Skip to main content
PLOS One logoLink to PLOS One
. 2021 Apr 21;16(4):e0249813. doi: 10.1371/journal.pone.0249813

Intimate partner violence is a barrier to antiretroviral therapy adherence among HIV-positive women: Evidence from government facilities in Kenya

Bornice C Biomndo 1,*,#, Alexander Bergmann 2,#, Nils Lahmann 3, Lukoye Atwoli 4,5,#
Editor: Michelle L Munro-Kramer6
PMCID: PMC8059826  PMID: 33882084

Abstract

Introduction

Intimate Partner Violence (IPV) is linked to low engagement with HIV management services and adverse clinical outcomes, including poor ART adherence. In sub-Saharan Africa, studies on pregnant/postpartum women and transactional sex workers have produced divergent evidence regarding IPV’s association with poor ART adherence. We investigate this association among a broad group of women.

Methods

We sampled 408 HIV-positive women receiving free ART from different types of HIV clinics at government health facilities, assessing for IPV exposure by a current partner, ART adherence rate, and other factors that affect ART adherence (e.g. education, disclosure). ART adherence rates were measured using the Visual Analogue Scale (VAS); responses were dichotomised at a ≥95% cut-off. Multiple logistic regression models assessed the association between the independent variables and ART adherence.

Results

The participants’ mean age was 38.6 (range: 18–69 years). The majority had ever attended school (94%, n = 382), were in monogamous marriages (70%, n = 282), and had disclosed status to partners (94%, n = 380). Overall, 60% (n = 242) reported optimal ART adherence (≥ 95%) in the previous 30 days. The prevalence of IPV by the current partner was 76% (CI95 = 72–80%). Experiencing physical IPV (AOR 0.57, CI95: 0.34–0.94, p = .028), sexual IPV (AOR 0.50, CI95: 0.31–0.82, p = .005), or controlling behaviour (AOR 0.56, CI95: 0.34–0.94, p = .027) reduced the odds of achieving optimal adherence, while a higher education level and having an HIV-positive partner increased the odds.

Conclusion

IPV is common and is associated with suboptimal ART adherence rates among a broad group of HIV-positive women. ART programs could consider incorporating basic IPV interventions into regular clinic services to identify, monitor and support exposed women, as they might be at risk of poor ART adherence. Still, there is need for more research on how IPV affects ART adherence.

Introduction

Intimate Partner Violence (IPV) is recognised as a factor behind low uptake and engagement with HIV management services [17]. IPV is defined as acts of physical aggression, sexual coercion, psychological/emotional abuse, or controlling behaviour by a former or current intimate partner [8]. Studies in resource-rich settings such as the United States of America and Canada estimate that 68–95% of HIV-positive women experience IPV [1,3]. Estimates available from sub-Saharan Africa report that the prevalence of the various forms of IPV among HIV-positive women ranges from 26% to 72% [3,911]. Studies from East Africa indicate that HIV-positive women are 2–10 times more likely to report lifetime IPV than their HIV-negative counterparts [1214]; one in three HIV-positive women experiences IPV [10]. In Kenya, population-based surveys indicate that, among women aged 15–49 years, the national IPV prevalence rate is 47% [15], while the national adult (≥15 years old) HIV prevalence rate is 5.2%, which is slightly higher than that of men (4.5%) [16].

Several studies that include women from sub-Saharan Africa have established a significant bidirectional association between IPV and positive HIV serology [1,4,1214,1719]. IPV is a risk factor for HIV infection among women [18,20] since women who experience it are more likely to be exposed to risky sexual behaviour, violent sexual acts, and forced sex [21,22]. Moreover, women who experience IPV are rarely in a position to negotiate for condom use and generally have reduced access to HIV testing or healthcare services [1,6,12,23]. Experiencing IPV can also result from a woman revealing her HIV-positive status (post-disclosure IPV). Reports indicate that a significant number of HIV-positive women experience IPV as a result of behaviour changes resulting from an HIV-positive diagnosis, a disclosure of positive status, or attempts to discuss HIV testing and treatment options [1,7,10,13,2326]. Actual IPV and fear of IPV is associated with non-disclosure, poor mental health, missing clinic appointments, and prioritising safety over medication compliance, which adversely affect HIV prevention and ART initiation, adherence, and retention strategies [1,6,19,25,2729].

Studies that explore the role of IPV in uptake and compliance with HIV management services link IPV to poor service uptake, poor medication adherence, and consequent virological failure, higher mortality, and increased episodic diseases [1,28,30]. In 2015, Hatcher et al. [1] noted in their systematic review that these findings were skewed towards resource-rich settings. A knowledge gap existed regarding this association in sub-Saharan Africa, which contains an estimated 12 million out of 17 million people receiving ART globally [31] and where IPV and HIV infection are prevalent and disproportionately affect women [1,6,32,33]. Recent studies from sub-Saharan Africa have aimed to fill this knowledge gap, yielding contrasting and inconclusive evidence. While some studies have established exposure to IPV as a risk factor for poor ART adherence among women [19,23] or associated IPV with reduced odds of ART adherence [7], others have found no significant association [34,35]. So far, the evidence from sub-Saharan Africa has been based on research among key populations, such as transactional sex workers and women at Prevention of Mother-to-Child Transmission (PMTCT) clinics. However, to determine whether IPV exerts an overarching influence on ART adherence, the association between both variables must be explored among a broader sample of HIV-positive women with diverse socioeconomic characteristics who are receiving the available standard ART from different types of HIV clinics.

In this observational study, we sought to determine the prevalence of IPV among HIV-positive women and explored the relationship between IPV exposure and ART adherence rates. We investigate whether physical IPV, sexual IPV, emotional IPV, and controlling behaviour are associated with self-reported suboptimal adherence among a sample of HIV-positive women (n = 408) receiving free ART at government facilities in western Kenya.

Conceptual framework

This study was guided by a combination of two conceptual frameworks. Firstly, we used the theoretical framework on ART adherence which stipulates that there are sociodemographic drivers which alongside treatment regime, provider-patient relationship, clinic setting, and disease characteristics, affect a patient’s level of medical adherence [3638]. More specifically, that there are socio-cultural and interpersonal factors (i.e. partner interference) which physically or psychologically undermine a woman’s ability or motivation to adhere to ART [1,29,3841]. Secondly, the WHO conceptual framework on the adverse health effects of IPV on women provides a structure for understanding the possible role IPV has in poor ART adherence. There are three key mechanisms and pathways: physical trauma, psychological trauma/stress, and fear and control. These can directly or indirectly lead to injury, mental health problems, limited control of one’s health and limited health care seeking behaviour [42], which could consequently interfere with ART adherence.

Materials and methods

Study design and setting

This cross-sectional survey was conducted in March and April 2018 at twelve HIV clinics in government health facilities in Kenya. The HIV clinics are part of the AMPATH (Academic Model Providing Access to Healthcare) partnership that cooperates with the Ministry of Health and a consortium of universities to offer free HIV care and treatment services [43]. At the time of the survey, there were 79,728 HIV-positive women (aged ≥15 years) enrolled in the ART program; 40,370 were actively receiving ART [44]. We selected six urban and six rural clinics for the survey based on their number of active HIV-positive women receiving ART; the clinics were chosen to account for the socioeconomic diversity of the counties served by the AMPATH partnership. We included large clinics with many women active on ART, as well as smaller health facilities that we purposively selected to represent less populous communities.

Study population

The study population consisted entirely of HIV-positive women who were actively receiving free ART at the HIV clinics. Eligible respondents were at least 18 years old, currently in an intimate partner relationship, and had begun ART at least six months before the survey. We set a minimum duration of six months since beginning ART in an effort to reduce factors affecting adherence that are related to the ART initiation. Additionally, according to the Kenya national ART guidelines, it is expected that at six months the clients should be compliant since they have sufficient understanding of HIV, medication dosage, their clinical progress, and the importance and benefits of ART adherence [45].

Sample size determination

The sample included 408 women. The sample size was calculated through a power proportion test [46] in R (stats package, R Core Team 2013), using the national IPV prevalence rate of 47% [47] as the proportion, at a power of 0.8 and a significance level of 0.05, and with the aim of conducting a logistic regression. Due to feasibility considerations, we decided to use the prevalence rate of physical violence (45%) as the proportion, in order to get a workable sample size and because it was the most reported form of violence among women [47]. Proportional stratified sampling was applied to determine the number of women to sample from each of the selected clinics. That is, the number of women active on ART at each clinic was weighed against the total number of women on ART at AMPATH to determine each clinic’s share of the total sample.

Data collection

IPV measurement

Exposure to physical IPV, sexual IPV, emotional IPV, and controlling behaviour by a current intimate partner was measured using the Demographic Health Survey (DHS) module on Domestic Violence. This module is a modified version of the Conflict Tactics Scale by Murray A. Straus and is widely used to measure spousal violence within the household context [4749]. An intimate partner is defined as someone to whom the woman was currently married (whether in a monogamous or polygamous marriage) or with whom she was in a romantic relationship. The DHS questions on IPV depict specific forms of physical IPV (e.g. slapping, kicking), sexual IPV (i.e. use of physical force or threats to have sexual intercourse), emotional IPV (e.g. humiliation, insults), and controlling behaviour (hindrance of social contact). Each can be answered with ‘No’ or ‘Yes’. A ‘Yes’ response to any question was considered to constitute exposure to IPV.

The DHS module on domestic violence measures both lifetime IPV and IPV within the previous 12 months by a current or former partner. By recruiting only women who were currently in a relationship, and slightly altering the DHS questions from ‘Did your (last) husband/partner ever. . .’ to ‘Did your husband/partner ever…’, we focused on exposure to IPV by a current partner within the lifetime of the ongoing relationship (relationship-specific IPV). Our interest was investigating whether being in an environment where IPV occurs affects the ability to adhere to ART.

ART adherence measurement

To measure ART adherence, we used the AIDS Clinical Trials Group (ACTG) Adherence Follow-up Questionnaire and the Brief Adherence Self-report. The latter contains a 30-day Visual Analogue Scale (VAS) commonly used in resource-limited settings because it is practical, easy to administer, inexpensive, and does not require high literacy levels [7,5053]. The participants were asked to best estimate the percentage of ARV dosage they took in the last 30 days by marking an X or O on the VAS line measuring from 0% to 100%. Selecting 0 indicated that they had taken none of the prescribed drugs; 100% meant they had not missed a single dose.

The DHS module on Domestic Violence and the ACTG Adherence Follow-up Questionnaire and Brief Adherence Self-report are validated measurement tools that have been used in similar populations and settings [7,31,32,5456]. Moreover, the ACTG Follow up and Self-report measures are one of several ways that the HIV clinics monitor client ART adherence rates; therefore, they were already familiar to both the recruiters and the participants.

For the other covariates, we used a broad set of socio-economic drivers which existing literature identifies as potentially affecting ART adherence: age, marital status, length of time on ART, education, income, HIV status disclosure, partner’s HIV status, social support from the partner (if the partner is involved in the woman’s ART), the partner’s alcohol consumption, and the area of living. The IPV and ART subscales and the questions concerning potentially relevant variables were combined into a four-page questionnaire administered in paper form.

Procedure

Participants were recruited from mixed HIV clinics (non-specialised clinics where female and male HIV-positive adults are reviewed and given medication refills), PMTCT clinics, maternal and child health clinics, and express clinics (for clients who are categorised as stable/virally suppressed, who therefore receive drug refills without rigorous review by a healthcare provider). The clinical officers and nurses who provide and supervise ART during regular clinical care visits recruited the participants. They were trained on the aim of the study, the tools, and the recruitment process (random selection, eligibility criteria). Randomised lists were created using Microsoft Excel, considering the number of clinical officers/nurses administering the questionnaires per clinic and the estimated number of female clients the healthcare provider attends to per day (retrieved from the daily clinic patient lists). Each healthcare provider received a randomised list which they used to recruit at least five women per day from their daily patient lists.

On completion of the routine clinical check-up in the regular clinic examination rooms, women whose session coincided with the random number from the list and who fit the study inclusion criteria were informed about the survey and asked if they were willing to participate. Prior to this, if the woman was accompanied by another person or a child who was old enough to understand the conversation and old enough be left alone, the person/child was politely asked to leave the examination room. The women were assured that participation or non-participation would not affect access to treatment. After they consented to participation, an informed consent form was provided, which they signed before the questionnaire was administered. Assistance was provided for those who could not read, needed clarification, or preferred that the questionnaire be administered as an interview. All of the consent forms and questionnaires were available in English and Kiswahili. Unfortunately, some of the rooms at the clinics were shared; healthcare providers were responsible for ensuring maximum possible privacy by, for example, asking colleagues to temporarily leave the room or by moving the desk or drawing a curtain. On completion of the survey, the women were given financial compensation (KSh 100) for their participation; this was referred to as ‘transport money’. Women who reported exposure to IPV were offered a list of places where they could receive free social and legal assistance within the health facility. The list also contained local government authorities, or non-governmental organisations in the area which were involved in gender-based violence prevention/women empowerment work.

Data analysis

Data from the questionnaires were entered and imported into R (Version 1.2.1335) for analysis. The responses regarding exposure to IPV were combined into five new variables: physical IPV, sexual IPV, emotional IPV, controlling behaviour, and overall exposure to IPV. If a woman answered ‘Yes’ to any of the questions on exposure to physical IPV, she was coded as ‘1’; if not, she was coded as ‘0’. The same was done for the other forms of IPV; overall exposure to IPV meant that the woman answered ‘Yes’ to any form of IPV.

Since our hypothesis was on relationship-specific IPV, our main analysis was based on exposure of IPV at any time within the relationship. However, to identify the possible impact of this decision on our results, we repeated the modelling procedure, with only women who were exposed to IPV in the last 12 months.

The responses to the VAS were used as the ART adherence outcome. Participants’ answers were dichotomised using the conservative optimal ART adherence level of ≥95% and suboptimal adherence of <95%, which was suggested by Paterson et al. [57] as necessary for achieving HIV viral suppression. We also performed a second analysis with a lower cut-off of ≥85% for comparison. Because both analyses yielded comparable results, we present analyses based on the more conservative cut off. We checked data quality and uni- and bivariate distributions using descriptive data analysis techniques. Since the questionnaire contained intimate questions that the participants could potentially skip, a missing value analysis was performed. None of the variables had more than 5% missing values. Additionally, no systematic relationships between the missing values were detected.

We used simple logistic regression models to examine the relationships between each of the independent variables and the dependent variable (ART adherence). Next, ART adherence was regressed stepwise for each of the independent variables. A possible limitation of regressing ART adherence on all independent variables together is that it prevents the identification of suppressor/moderator effects and runs the risk of overfitting the model. Assumptions were checked before conducting all logistic regression analyses; log likelihood-based Pseudo R2 measures and AIC scores were used to evaluate goodness of fit. Due to multicollinearity between the IPV variables, we decided to report four multiple logistic regression models, each of which includes only one IPV variable alongside the other independent variables. Despite the nested structure of our data (multiple women clustered in each of the 12 clinics), we decided against a multilevel modelling procedure. The low intraclass correlation coefficient of ICC = .15 that we derived from an unconditional multilevel logistic regression implies that only 15% of the individual variation in the underlying propensity of low ART uptake is due to systematic differences between the clinics [58,59]. Additionally, with as few as 12 clusters, fixed-effect estimates associated with level-2 predictors could have been severely biased [60,61]. We also did not include clinics as a fixed effect in our main analysis because adding 12 additional dummy coded variables to the analysis would have led to predictor combinations with very few to zero observations. However, we performed a sensitivity analysis in which clinic was added as a predictor variable. We identified significant differences among the clinics but there were no significant changes in the respective model parameter estimates from previous models (S3 Table).

Ethical considerations

Ethical approval was granted by the Moi University/Moi Teaching and Referral Hospital Institutional Research and Ethics Committee (IREC). Consent to participate was established through a written Informed Consent Form that the women signed.

Results

ART adherence and the prevalence of IPV in the current relationship

As shown in Table 1, the mean age of the participants was 38.6 years (range: 18–69 years old) and average time on ART was 78.8 months. The majority (94%, n = 382) had ever attended school, although only 13% had an education higher than secondary school (n = 49). Most women were in monogamous marriages (70%, n = 282), had disclosed their HIV-positive status to their partners (94%, n = 380), and knew that their partner was HIV-positive (64%, n = 260) (Table 1). Overall, 60% (n = 242) reported achieving optimal adherence (≥ 95%) in the last month. A large majority (76%, CI95 = 72–80%) of the women reported exposure to a form of IPV from their current partner. Of those exposed to IPV, 75% (CI95 = 71–79%) had experienced emotional IPV; 70% had experienced physical IPV (CI95 = 66–74%); 49% reported sexual IPV (CI95 = 44–54%); and 39% (CI95 = 34–44%) reported controlling behaviour from their current partner. When narrowed down to IPV exposure in the last 12 months, 72% (CI95 = 68–76%) had experienced emotional IPV; 53% had experienced physical IPV (CI95 = 48–58%); 40% reported sexual IPV (CI95 = 35–45%); and 45% (CI95 = 40–50%) reported controlling behaviour.

Table 1. Participant’s demographics, total and relative frequencies of IPV, and other variables stratified by optimal or suboptimal ART adherence.

Independent Variable ART Adherence
Total Suboptimal (<95%) Optimal (>95%)
Mean SD Mean SD Mean SD
Age in years 38.6 8.5 37.7 8.5 39.2 8.4
Length of time on ARVs in months 78.8 48.5 73.3 44.4 81.9 50.5
n % n % n %
Physical IPV No 189 (46.7) 62 (38.0) 127 (52.5)
Yes 216 (53.3) 101 (62.0) 115 (47.5)
Sexual IPV No 255 (63.0) 86 (52.8) 169 (69.8)
150 (37.0) 77 (47.2) 73 (30.2)
Emotional IPV No 170 (42.0) 55 (33.7) 115 (47.5)
Yes 235 (58.0) 108 (66.3) 127 (52.5)
Controlling Behaviour No 286 (70.6) 100 (61.3) 186 (76.9)
Yes 119 (29.4) 63 (38.7) 56 (23.1)
Education None 24 (5.9) 13 (7.9) 11 (4.5)
Primary 224 (55.2) 87 (53.0) 137 (56.6)
Secondary 109 (26.8) 55 (33.5) 54 (22.3)
Tertiary 49 (12.1) 9 (5.5) 40 (16.5)
Marital Status In a relationship 33 (8.1) 17 (10.4) 16 (6.6)
Monogamous marriage 282 (69.6) 102 (62.6) 180 (74.4)
Polygamous marriage 90 (22.2) 44 (27.0) 46 (19.0)
Disclosure No 25 (6.2) 14 (8.6) 11 (4.5)
Yes 380 (93.8) 149 (91.4) 231 (95.5)
Partner (HIV-positive) No 145 35.8) 69 (42.3) 76 (31.4)
Yes 260 (64.2) 94 (57.7) 166 (68.6)
Partner accompanies to clinic/reminds to take ARV No 176 (43.7) 84 (52.2) 92 (38.0)
Yes 227 (56.3) 77 (47.8) 150 (62.0)
Partner is drunk Never 210 (51.8) 73 (44.8) 137 (56.6)
Sometimes 121 (29.9) 58 (35.6) 63 (26.0)
Often 74 (18.3) 32 (19.6) 42 (17.4)
Woman in violence No 345 (85.2) 128 (78.5) 217 (89.7)
Yes 17 (4.2) 9 (5.5) 8 (3.3)
Fights back 43 (10.6) 26 (16.0) 17 (7.0)
Area Rural 163 (40.2) 80 (49.1) 83 (34.3)
Urban 242 (59.8) 83 (50.9) 159 (65.7)

Note. SD = Standard Deviation.

Logistic regression of ART on IPV

Simple regression analyses of the IPV variables and ART adherence revealed that all forms of IPV were significantly correlated to suboptimal ART adherence. As shown in Table 2, when adjusted for other factors affecting ART adherence, physical IPV, sexual IPV and controlling behaviour remained significant. HIV-positive women on ART who reported ever being exposed to physical IPV (AOR 0.57, CI95: 0.34–0.94, p = .028), sexual IPV (AOR 0.50, CI95: 0.31–0.82, p = .005), or controlling behaviour (AOR 0.56, CI95: 0.34–0.94, p = .027) were less likely to report ART adherence levels of 95% and over (Table 2). Tertiary education is positively correlated with the odds of achieving optimal ART adherence, except when analysed alongside exposure to emotional IPV (AOR 4.50, CI95: 0.99–21.80, p = .056). Women who knew their partners were also HIV-positive were more likely to report optimal ART adherence. This positive effect remains significant when analysed alongside exposure to physical IPV (AOR 1.70, CI95: 1.03–2.81, p = .040) and sexual IPV (AOR 1.69, CI95: 1.02–2.80, p = .040); this effect is insignificant when adjusted for controlling behaviour (AOR 1.60, CI95: 0.98–2.63, p = .062).

Table 2. Multiple regression models of factors associated with ART adherence.

Predictor Variable Dependent variable = ART
Model 1 Model 2 Model 3 Model 4
AOR 95% CI p AOR 95% CI p AOR 95% CI p AOR 95% CI p
Physical IPV (None)
Yes 0.57 0.34–0.94 .028*
Sexual IPV (None)
Yes 0.50 0.31–0.81 .005**
Emotional IPV (None)
Yes 0.65 0.39–1.10 .108
Controlling Behaviour (None)
Yes 0.56 0.34–0.94 .027*
Age 1.02 0.99–1.05 .145 1.02 0.99–1.05 .129 1.02 0.99–1.05 .140 1.02 0.99–1.05 .191
TARV 1.00 0.99–1.00 .529 1.00 0.99–1.00 .556 1.00 0.99–1.00 .499 1.00 0.99–1.00 .662
Education (None)
Primary 2.23 0.80–6.26 .124 2.16 0.78–6.03 .136 2.09 0.76–5.77 .151 2.01 0.73–5.52 .173
Secondary 1.29 0.44–3.81 .640 1.30 0.44–3.80 .635 1.22 0.42–3.55 .713 1.24 0.43–3.61 .687
Tertiary 5.17 1.12–25.67 .039* 5.71 1.25–28.10 .028* 4.48 0.99–21.81 .560 4.64 1.02–22.58 .050*
Marital Status (In a relationship)
Monogamous marriage 1.79 0.77–4.17 .175 1.44 0.62–3.79 .387 1.65 0.71–4.00 .237 1.63 0.70–3.76 .248
Polygamous marriage 1.03 0.41–2.60 .989 0.89 0.35–2.21 .797 0.94 0.38–2.34 .900 0.95 0.38–2.35 .904
Area (Rural)
Urban 1.31 0.81–2.12 .271 1.31 0.81–2.13 .268 1.28 0.79–2.07 .317 1.276 0.79–2.07 .320
Partner`s Alcohol Consumption (None)
Sometimes 0.71 0.42–1.20 .202 0.68 0.40–1.15 .150 0.72 0.43–1.23 .233 0.67 0.40–1.140 .140
Often 1.60 0.79–3.33 .199 1.85 0.76–1.37 .240 1.57 0.78–3.25 .215 1.44 0.72–2.94 .315
Partner’s HIV Status (Negative)
Positive 1.70 1.03–2.81 .037* 1.69 1.03–2.80 .039* 1.60 0.97–2.62 .064 1.60 0.97–2.63 .062
Supporting partner (No)
Yes 1.24 0.75–2.06 .398 1.23 0.74–2.03 .434 1.23 0.74–2.03 .431 1.28 0.77–2.13 .331
Woman is Violent (No)
Yes 0.46 0.16–1.33 .152 0.46 0.16–1.31 .145 0.47 0.16–1.34 .157 0.50 0.17–1.46 .200
Fights back 0.49 0.23–1.02 .056 0.48 0.22–1.01 .055 0.45 0.21–0.94 .035* 0.44 0.21–0.93 .031*
R2 Hosmer & Lemeshow .11 .11 .10 .11
R2 Cox & Snell .13 .14 .12 .13
R2Nagelkerke .18 .19 .17 .18

a AOR, adjusted odds ratio; b C.I, Confidence Interval; c *p < .05. **p < .01. ***p < .001; d R2, Pseudo R2.

The analysis including only women who reported experiencing IPV in the last 12 months revealed similar results (S2 Table). All forms of IPV significantly correlated to suboptimal ART adherence, even when regressed alongside other covariates; physical IPV (AOR 0.58, CI95: 0.34–0.98, p = .044), sexual IPV (AOR 0.52, CI95: 0.30–0.88, p = .016), emotional IPV (AOR 0.53, CI95: 0.31–0.90, p = .021), and controlling behaviour (AOR 0.56, CI95: 0.33–0.93, p = .026). Higher levels of education and having an HIV-positive partner (when adjusted for physical and sexual IPV) also significantly increased the odds of reporting optimal ART adherence among this subgroup.

Discussion

In our cross-sectional survey among a broad group of HIV-positive women on ART attending different types of free HIV clinics in government facilities, we examine the prevalence of IPV within the current relationship and its correlation to optimal and suboptimal ART adherence. Our findings reveal a high prevalence of IPV by the current intimate partner and a negative association between exposure to physical IPV, sexual IPV, or controlling behaviour, and odds of achieving optimal ART adherence.

Prevalence of IPV in the current relationship

Our analyses showed a high prevalence of IPV by the current intimate partner, at 76% (CI95 = 72–80%). This is significantly higher than the national average (47%) [47]. This was expected, since existing literature indicates that, globally, the lifetime prevalence of IPV among HIV-positive women is high [3,7,11] and greater than that of the general population [1,5,11,12,62]. Our results mirror those of other East African studies [9,11], which also established emotional IPV as the most-reported form of (lifetime and recent) IPV among HIV-positive women. This is followed by physical IPV and sexual IPV. Our study also measured the prevalence of controlling behaviour (39%, CI95 = 34–44%), which few previous studies have done, despite the small but growing evidence of its adverse health effects [17,63,64]. Although we had anticipated that some women would hesitate to participate in the survey due to the sensitive nature of the topic, all of the healthcare providers reported that the women willingly and openly discussed IPV. This is perhaps because IPV is generally considered a normal, acceptable occurrence in many communities [12,65]. Additionally, IPV is discussed regarding treatment challenges and was not a new topic to most of the participants or healthcare providers.

ART adherence

Overall, the ART adherence level was high among the women surveyed, with 75% reporting adherence rates of 90% and above. This may result from the women giving socially desirable answers. However, since the survey was done immediately after the routine clinical check-up, which includes a review of the viral load and discussions regarding challenges with medication, we believe there was an increased likelihood that the women gave mostly honest responses. Therefore, the high adherence rates may be credited to the provision of free comprehensive ART and to the vigorous clinic- and community-based patient monitoring and follow-up strategies available. Moreover, the clinics are distributed to reduce travel time and costs. Without these accommodations, patient access and retention in care could be negatively affected [19,66,67]. The high ART adherence rates could also be connected to the high disclosure rate among this group of women. Of the women we surveyed, 94% (n = 380) had disclosed their status to their current partner. According to Tam et al. [68], on average, approximately 63% of pregnant and post-partum HIV-positive women in sub-Saharan Africa disclose their status to their partners. The higher disclosure rate among our study participants may be due to the broader nature of our sample. It could also be attributed to interventions such as free professional counselling, couple counselling, peer support groups, and social and legal support, which are available at the clinics to help clients address factors that may affect their ART adherence. Non-disclosure is a known barrier to optimal ART adherence because it can result in hesitancy in attending clinic appointments, concealment of ARVs, fear, and a lack of social support [19,68,69]. Moreover, in her study on IPV among HIV-positive women, Hampanda [7] reported that disclosure of HIV-positive status to a partner was associated with increased medication adherence. The low number of women who had not disclosed their status among our participants may account for why the ‘disclosure’ variable was statistically insignificant, according to the bivariate analysis against ART adherence. Therefore, we did not include it in the multiple logistic regression to avoid inflating the model.

ART adherence and IPV

Considering an optimal adherence level of ≥95% to analyse the association between exposure to IPV and ART adherence while controlling for other factors, we identified IPV as an independent risk factor for suboptimal ART adherence. Experiencing physical IPV (AOR 0.57, CI95: 0.343–0.938, p = .028), sexual IPV (AOR 0.499, CI95: 0.306–0.810, p = .005), or controlling behaviour (AOR 0.563, CI95: 0.337–0.936, p = .027) from a current intimate partner reduced the odds of an HIV-positive woman reporting optimal ART adherence rates. This finding corroborates studies that link IPV to poor adherence to ARV therapy among women [1,7,70]. According to the healthcare providers in our study, lower adherence among this group of women can be partly attributed to the fact that, during some IPV encounters, some women are chased or forced to flee their homes. In this stressful situation, they may forget to carry their medication; their newfound refuge may make it difficult to maintain their medication schedule or clinic appointments. Moreover, research on IPV reveals that experiencing IPV can lead to psychological distress, depression, and poor mental health [7,28,37,41,62,63] which are predictors of lower ART adherence rates. This could also be an explanation behind the impact IPV has on ART adherence [1,28].

Our findings contrast with those of some studies, such as Gichane et al. [34] and Wilson et al. [35], who found no significant association between IPV and ART adherence among various groups of women in sub-Saharan Africa. The difference in findings may result from several factors. Wilson et al.’s [71] study on women engaged in transactional sex work found no evidence that exposure to IPV was associated with suboptimal (<80%) self-rated ART adherence. One explanation for the difference in findings is that, while we engaged a broader random sample of women who could have a high or low risk of experiencing IPV, Wilson et al. [35] focused on women involved in transactional sex work; this subgroup experiences high rates of overall violence and IPV. These different findings may also result from differences in the recruitment process or IPV measurement, since they annually assessed exposure to IPV in the previous 12 months by a current or former emotional partner while we investigated relationship-specific IPV. Additionally, Wilson et al. noted that their participants were receiving socioeconomic benefits such as transport reimbursement during regular clinic visits, which could have motivated them to be more adherent. Our research differs from Gichane et al.’s [34] study on pregnant and postpartum HIV-positive women in terms of the sample population and measurement. While we used a one-time recording of self-reported adherence at a ≥95% cut-off, Gichane et al. used cumulative ART adherence based on an optimal adherence cut-off of 100% and recorded over multiple clinic visits. Their study is comparable to that of Hampada et al. [14] in terms of sample population and study design. However, the latter found IPV to be associated with reduced odds of adherence among pregnant and postpartum HIV-positive women.

Other covariates of ART adherence

Our results indicate that having a tertiary education positively correlates with optimal ART adherence, even when adjusted for IPV exposure and other factors. This aligns with previous research findings showing higher adherence rates among HIV-positive women with higher education compared to their counterparts with little or no education [19,72]. However, it should be noted that the tertiary education subgroup had only 49 respondents, which led to small or no cell numbers for some predictor combinations. Having an HIV-positive partner positively correlated with higher optimal ART adherence rates. This effect remained significant even when adjusted for other factors and exposure to physical IPV and sexual IPV. However, this positive association with optimal ART adherence does not hold when the woman experiences controlling behaviour from the intimate partner. Likewise, women who fought back during IPV encounters had reduced odds of achieving optimal adherence when adjusted for exposure to controlling behaviour, but not when adjusted for physical IPV or sexual IPV. Violence by women during IPV encounters is not uncommon and is known to stem from the need for self-defence, protection of the children, or from fear of severe injury [7375]. Our findings suggest that the act of fighting back has no effect on ART adherence except in an environment in which controlling behaviour and emotional IPV occurs. We interpret this as being supportive of studies that emphasise the importance of considering controlling behaviour as an independent form of IPV, because it may exert additional effects apart from the other forms of IPV and may also be psychologically more detrimental than previously estimated [17,64]. Since many previous studies had focused on HIV-positive women in PMTCT programs, we examined whether expectant women in our sample would stand out from the group. Pregnancy as an independent variable did not prove significant when we conducted both bivariate analysis against ART adherence and multiple logistic regression. However, this could stem from the low number of pregnant participants (n = 14). Based on the latest Demographic Health Statistics, we expected about 6% (n = >24) of the women to be pregnant [47].

Limitations

We recognise several limitations to our research. First, the VAS (like other self-reporting tools) is subject to recall bias (which may cause overestimation) and is prone to eliciting socially desirable responses. Nevertheless, there is sufficient evidence demonstrating that self-report tools correlate with other objective measurement tools, are associated with plasma drug levels, and are useful for identifying vulnerable patients [53,54,76]. Additionally, the questionnaire was administered by the participants’ regular healthcare providers, with whom they were familiar and had possibly built a trusted relationship. As mentioned previously, the survey was conducted after the routine clinical check-up, which includes a review of the viral load and ART adherence rate, and discussions on treatment challenges and general wellbeing. We believe that the system for administering the survey increased the likelihood of attaining honest responses from the participants.

Second, we acknowledge that using the ≥95% cut-off to represent optimal ART adherence is controversial because it is based on obsolete therapy; advanced agent combinations can now effectively suppress the HIV viral load at lower ART adherence levels. Therefore, we reran the analysis using a lower cut-off (≥85%) and found that the results converge, with the only difference being that women whose partners ‘sometimes got drunk’ or who were ‘sometimes afraid of their partners’ also had lower odds of achieving ART adherence at the ≥85% cut-off. We are, therefore, confident that our findings on the effects of IPV are robust. The decision to measure exposure to IPV within the current intimate relationship (regardless of when it occurred) and compare it to 30-day self-reported ART adherence could limit our ability to associate IPV with suboptimal ART adherence. However, our interest was investigating whether past or ongoing IPV within the relationship impacted ART adherence. Our rationale is that specific IPV incidents may not affect medication adherence, but living in an environment in which IPV occurs does influence a woman’s ability to maintain optimal ART adherence. This is further supported by the fact that the second analysis, which we ran including only the women who experienced IPV in the last 12 months, revealed similar results to the relationship-specific analysis.

Due to resource limitations, we were unable to expand our capacity to capture cases of defaulters whose adherence (to clinic appointments or medication) reduced over time until they ultimately dropped out of the program. These are perhaps the most vulnerable group and future research should consider tracking them down to establish their reason for attrition. Additionally, the cross-sectional nature of the study means that no temporality can be inferred; therefore, we cannot make any causality inferences. Nevertheless, we believe our findings are useful, as they contribute evidence for an association between IPV and undesirable clinical outcomes. We also offer insight into where strategies can be introduced to improve ART adherence outcomes.

On the other hand, our study has several strengths. First, we randomly recruited women of diverse ages (18–69 years) receiving ARV treatment in different types of free HIV clinics at government health facilities. This indicates that our sample accounted for the varying characteristics of women receiving ART in Kenya. Previous studies have tended to focus on key populations (and rightly so), participants of ongoing trials, or couples jointly participating in interventions, which can limit the generalisability of results.

Conclusion and future practices

Despite the great advances in ART such as increased drug efficacy, improved access to ARVs, and convenient regimens, achieving optimal ART adherence remains a challenge among some groups. As Shubber et al [67] noted, there is no single intervention that will be sufficient to ensure high levels of ART adherence. What is needed is a combination of interventions that aim at strengthening aspects or undermining barriers which are linked to adherence. Similar to some existing studies, our findings show a high prevalence of IPV among HIV-positive women, less than optimal ART adherence rates, and a significant negative association between IPV and optimal ART adherence. Therefore, basic screening for exposure to IPV by healthcare providers could help in early identification, monitoring, and extra support for exposed women since we believe they are at risk of poor ART adherence. Moreover, since it is already established that IPV has negative effects on women’s health [22,64,77,78], any reduction of the harmful effects would generally improve the HIV-positive women’s quality of life. The IPV screening could be integrated at the earlier stages of ART initiation. Alternatively, it could be done at the healthcare provider’s discretion, based on the woman’s responsiveness to the therapy. The clinical officers and nurses involved in this study reported that participants willingly discussed their IPV experience. The former also expressed interest in receiving training on IPV. A review on programs in sub-Saharan Africa which have implemented IPV screening and counselling services in healthcare settings, reported that the interventions were positively received by both healthcare providers and clients [2]. Healthcare workers could therefore be navigation points for women exposed to IPV who are willing to be assisted.

Nevertheless, there is need for future research to investigate further how IPV affects ART adherence. One recommendation would be to focus the studies on women with poor ART adherence and also tracking down women who drop out of ART programs. Furthermore, controlling behaviour remains an underestimated and thus understudied form of IPV despite growing evidence of its adverse effects. We encourage future researchers to consider including it in their investigations.

Supporting information

S1 Table. Propotional stratified sampling based on the number of women on ART and location of clinic.

(DOCX)

S2 Table. Multiple regression models of factors associated with ART adherence among women who experienced IPV in the last 12 months.

(DOCX)

S3 Table. Multiple regression models of factors associated with ART adherence including clinics as a predictor variable.

(DOCX)

Acknowledgments

We would like to thank the Ministry of Health/AMPATH clients for agreeing to participate in this survey. We extend our gratitude to the healthcare providers for administering the questionnaires and interacting with the women. We thank the Ministry of Health/AMPATH leadership for making this research possible.

Data Availability

We have uploaded our data set to Zenodo and it is available via the following URL: https://zenodo.org/record/4135394#.YGNt469Kg2x (DOI: 10.5281/zenodo.4135394).

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Hatcher AM, Smout EM, Turan JM, Christofides N, Stockl H. Intimate partner violence and engagement in HIV care and treatment among women: a systematic review and meta-analysis. Aids. 2015. October 23;29(16):2183–94. 10.1097/QAD.0000000000000842 . [DOI] [PubMed] [Google Scholar]
  • 2.Young CR, Arnos DM, Matthews LT. A scoping review of interventions to address intimate partner violence in sub-Saharan African healthcare. Global public health. 2019. September;14(9):1335–46. 10.1080/17441692.2019.1567802 . Pubmed Central PMCID: 6635092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kouyoumdjian FG, Findlay N, Schwandt M, Calzavara LM. A systematic review of the relationships between intimate partner violence and HIV/AIDS. PloS one. 2013. November 25;8(11). WOS:000327543500068. 10.1371/journal.pone.0081044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Li Y, Marshall CM, Rees HC, Nunez A, Ezeanolue EE, Ehiri JE. Intimate partner violence and HIV infection among women: a systematic review and meta-analysis. Journal of the International AIDS Society. 2014. February 13;17. WOS:000331694700001. 10.7448/IAS.17.1.18845 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Trimble DD, Nava A, McFarlane J. Intimate partner violence and antiretroviral adherence among women receiving care in an urban Southeastern Texas HIV clinic. The Journal of the Association of Nurses in AIDS Care: JANAC. 2013. Jul-Aug;24(4):331–40. 10.1016/j.jana.2013.02.006 . [DOI] [PubMed] [Google Scholar]
  • 6.WHO. Violence against women and HIV/AIDS: critical intersections. Intimate partner violence and HIV/AIDS. World Health Organisation, 2004. [Google Scholar]
  • 7.Hampanda KM. Intimate partner violence and HIV-positive women’s non-adherence to antiretroviral medication for the purpose of prevention of mother-to-child transmission in Lusaka, Zambia. Soc Sci Med. 2016. March;153:123–30. WOS:000372937500015. 10.1016/j.socscimed.2016.02.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Heise L. G-MC. Intimate partner violence. WHO Report. Geneva: World Health Organisation, 2002. [Google Scholar]
  • 9.Meskele M, Khuzwayo N, Taylor M. Intimate partner violence against women living with and without HIV, and the associated factors in Wolaita Zone, Southern Ethiopia: A comparative cross-sectional study. PloS one. 2019;14(8):e0220919. 10.1371/journal.pone.0220919 . Pubmed Central PMCID: 6707594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Osinde MO, Kaye DK, Kakaire O. Intimate partner violence among women with HIV infection in rural Uganda: critical implications for policy and practice. BMC women’s health. 2011. November 17;11:50. 10.1186/1472-6874-11-50 . Pubmed Central PMCID: 3231867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ogbonnaya IN, Wanyenze RK, Reed E, Silverman JG, Kiene SM. Prevalence of and risk factors for intimate partner violence in the first 6 months following HIV diagnosis among a population-based sample in rural Uganda. AIDS and behavior. 2020. April;24(4):1252–65. 10.1007/s10461-019-02673-8 . Pubmed Central PMCID: 7080600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fonck K, Leye E, Kidula N, Ndinya-Achola J, Temmerman M. Increased risk of HIV in women experiencing physical partner violence in Nairobi, Kenya. AIDS and behavior. 2005. September;9(3):335–9. 10.1007/s10461-005-9007-0 . [DOI] [PubMed] [Google Scholar]
  • 13.Kiarie JN, Farquhar C, Richardson BA, Kabura MN, John FN, Nduati RW, et al. Domestic violence and prevention of mother-to-child transmission of HIV-1. Aids. 2006. August 22;20(13):1763–9. WOS:000240524300010. 10.1097/01.aids.0000242823.51754.0c [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Maman S, Mbwambo JK, Hogan NM, Kilonzo GP, Campbell JC, Weiss E, et al. HIV-positive women report more lifetime partner violence: findings from a voluntary counseling and testing clinic in Dar es Salaam, Tanzania. American journal of public health. 2002. August;92(8):1331–7. 10.2105/ajph.92.8.1331 . Pubmed Central PMCID: 1447239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kenya National Bureau of Statistics, Ministry of Health/Kenya, National AIDS Control Council/Kenya, Kenya Medical Research Institute, Population NCf, Development/Kenya. Kenya Demographic and Health Survey 2014. Rockville, MD, USA: 2015.
  • 16.NACC/NASCOP. Kenya HIV Estimates 2018. Nairobi, Kenya: Ministry of Health, 2018.
  • 17.Durevall D, Lindskog A. Intimate partner violence and HIV in ten sub-Saharan African countries: what do the Demographic and Health Surveys tell us? Lancet Glob Health. 2015. January;3(1):e34–43. 10.1016/S2214-109X(14)70343-2 . [DOI] [PubMed] [Google Scholar]
  • 18.Shi CF, Kouyoumdjian FG, Dushoff J. Intimate partner violence is associated with HIV infection in women in Kenya: a cross-sectional analysis. BMC public health. 2013. May 28;13:512. 10.1186/1471-2458-13-512 . Pubmed Central PMCID: 3702473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hodgson I, Plummer ML, Konopka SN, Colvin CJ, Jonas E, Albertini J, et al. A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-Infected pregnant and postpartum women. PloS one. 2014. November 5;9(11). WOS:000344556900047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jewkes RK, Dunkle K, Nduna M, Shai N. Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study. Lancet. 2010. July 3;376(9734):41–8. 10.1016/S0140-6736(10)60548-X . [DOI] [PubMed] [Google Scholar]
  • 21.Dunkle KL, Decker MR. Gender-based violence and HIV: reviewing the evidence for links and causal pathways in the general population and high-risk groups. American journal of reproductive immunology. 2013. February;69 Suppl 1:20–6. 10.1111/aji.12039 . [DOI] [PubMed] [Google Scholar]
  • 22.Garcia-Moreno C, Jansen HA, Ellsberg M, Heise L, Watts CH, Health WHOM-cSoWs, et al. Prevalence of intimate partner violence: findings from the WHO multi-country study on women’s health and domestic violence. Lancet. 2006. October 7;368(9543):1260–9. 10.1016/S0140-6736(06)69523-8 . [DOI] [PubMed] [Google Scholar]
  • 23.Winchester MS. Synergistic vulnerabilities: Antiretroviral treatment among women in Uganda. Global public health. 2015. August 9;10(7):881–94. WOS:000359350300007. 10.1080/17441692.2015.1007468 [DOI] [PubMed] [Google Scholar]
  • 24.Brooks RD JP, Marsh L, Velazquez JM, Padilla L, Jaoko WG. Intimate partner violence among HIV-positive women in Nairobi, Kenya. International journal of women’s health. 2019;11: Pages 451–61 Epub 19th August 2019. 10.2147/IJWH.S203327 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ezebuka O, Sam-Agudu N, Erekaha S, Dairo M. Correlates of intimate partner violence among HIV-positive women in southwest Nigeria. The Lancet Global Health. 2015;3:S23. [Google Scholar]
  • 26.Shamu S, Zarowsky C, Shefer T, Temmerman M, Abrahams N. Intimate partner violence after disclosure of HIV test results among pregnant women in Harare, Zimbabwe. PloS one. 2014. October 28;9(10). WOS:000343943100012. 10.1371/journal.pone.0109447 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Seth P, Kidder D, Pals S, Parent J, Mbatia R, Chesang K, et al. Psychosocial functioning and depressive symptoms among HIV-positive persons receiving care and treatment in Kenya, Namibia, and Tanzania. Prevention Science. 2014. June;15(3):318–28. WOS:000336283200007. 10.1007/s11121-013-0420-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Siemieniuk RA, Krentz HB, Miller P, Woodman K, Ko K, Gill MJ. The clinical implications of high rates of intimate partner violence against HIV-positive women. Journal of acquired immune deficiency syndromes. 2013. September 1;64(1):32–8. 10.1097/QAI.0b013e31829bb007 . [DOI] [PubMed] [Google Scholar]
  • 29.Orza L, Bass E, Bell E, Crone ET, Damji N, Dilmitis S, et al. In Women’s Eyes: Key Barriers to Women’s Access to HIV Treatment and a Rights-Based Approach to their Sustained Well-Being. Health and human rights. 2017. December;19(2):155–68. WOS:000418343900017. English. [PMC free article] [PubMed] [Google Scholar]
  • 30.Schafer KR, Brant J, Gupta S, Thorpe J, Winstead-Derlega C, Pinkerton R, et al. Intimate partner violence: a predictor of worse HIV outcomes and engagement in care. AIDS patient care and STDs. 2012. June;26(6):356–65. 10.1089/apc.2011.0409 . Pubmed Central PMCID: 3366337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Bijker R, Jiamsakul A, Kityo C, Kiertiburanakul S, Siwale M, Phanuphak P, et al. Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts. Journal of the International AIDS Society. 2017. March 3;20(1):21218. 10.7448/IAS.20.1.21218 . Pubmed Central PMCID: 5467608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Onsomu EO, Abuya BA, Okech IN, Rosen DL, Duren-Winfield V, Simmons AC. Association between domestic violence and HIV serostatus among married and formerly married women in Kenya. Health care for women international. 2015;36(2):205–28. 10.1080/07399332.2014.943840 . Pubmed Central PMCID: 4312516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Nelson KA, Ferrance JL, Masho SW. Intimate partner violence, consenting to HIV testing and HIV status among Zambian women. International journal of STD & AIDS. 2016. September;27(10):832–9. 10.1177/0956462415596299 . [DOI] [PubMed] [Google Scholar]
  • 34.Gichane MW, Moracco KE, Thirumurthy H, Okitolonda EW, Behets F, Yotebieng M. Intimate partner violence and prevention of mother to child transmission of HIV: Evidence from Kinshasa, Democratic Republic of Congo. PloS one. 2018. August 30;13(8). WOS:000443388900128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Wilson KS, Wanje G, Yuhas K, Simoni JM, Masese L, Vander Stoep A, et al. A prospective study of intimate partner violence as a risk factor for detectable plasma viral load in HIV-positive women engaged in transactional sex in Mombasa, Kenya. AIDS and behavior. 2016. May 3. 10.1007/s10461-016-1420-z . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. Journal of clinical epidemiology. 1997. April;50(4):385–91. 10.1016/s0895-4356(97)00041-3 . [DOI] [PubMed] [Google Scholar]
  • 37.Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. Journal of acquired immune deficiency syndromes. 2002. December 15;31 Suppl 3:S123–7. 10.1097/00126334-200212153-00007 . [DOI] [PubMed] [Google Scholar]
  • 38.Hatcher AM, Woollett N, Pallitto CC, Mokoatle K, Stockl H, MacPhail C, et al. Bidirectional links between HIV and intimate partner violence in pregnancy: implications for prevention of mother-to-child transmission. Journal of the International AIDS Society. 2014;17:19233. 10.7448/IAS.17.1.19233 . Pubmed Central PMCID: 4220001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Cohen MH, Cook JA, Grey D, Young M, Hanau LH, Tien P, et al. Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. American journal of public health. 2004. July;94(7):1147–51. 10.2105/ajph.94.7.1147 . Pubmed Central PMCID: 1448413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Lichtenstein B. Domestic violence in barriers to health care for HIV-positive women. AIDS patient care and STDs. 2006. February;20(2):122–32. 10.1089/apc.2006.20.122 . [DOI] [PubMed] [Google Scholar]
  • 41.Fiorentino M, Sagaon-Teyssier L, Ndiaye K, Suzan-Monti M, Mengue MT, Vidal L, et al. Intimate partner violence against HIV-positive Cameroonian women: Prevalence, associated factors and relationship with antiretroviral therapy discontinuity-results from the ANRS-12288 EVOLCam survey. Women’s health. 2019. Jan-Dec;15:1745506519848546. 10.1177/1745506519848546 . Pubmed Central PMCID: 6558534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.García-Moreno C, Pallitto C, Devries K, Stöckl H, Watts C, Abrahams N, et al. Global and regional estimates of violence against women: prevalence and health effects of intimate partner violence and non-partner sexual violence. Geneva, Switzerland: World Health Organization; 2013. vi, 50 pages p. [Google Scholar]
  • 43.Kwobah C, Mwangi A, Koech J, Simiyu G, Siika A. Factors associated with first-line antiretroviral therapy failure amongst HIV-infected African patients: A case-control study. World Journal of AIDS. 2012;02(04):271–8. [Google Scholar]
  • 44.Programme NASC. MOH 731—Comprehensive HIV/AIDS Facility Reporting Form. Report. Programme NASC; 2018 MOH 731.
  • 45.NASCOP. Guidelines for Antiretroviral Therapy in Kenya. Nairobi Kenya: National AIDS and STI Control Program, 2011.
  • 46.Jones SR, Carley S, Harrison M. An introduction to power and sample size estimation. Emergency medicine journal: EMJ. 2003. September;20(5):453–8. 10.1136/emj.20.5.453 . Pubmed Central PMCID: 1726174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Marco Ka. 2014 Kenya Demographic and Health Survey (KDHS). Calverton, Maryland: KNBS and ICF Marco, 2014.
  • 48.Kishor S, Johnson K, ORC Macro. MEASURE/DHS+ (Programme). Profiling domestic violence: a multi-country study. Calverton, MD: MEASURE DHS+, ORC Macro; 2004. xviii, 120 p. p. 10.1078/0176-1617-01156 [DOI] [PubMed] [Google Scholar]
  • 49.Strauss MA. Measuring intra-family conflict and violence—Conflict Tactics Scales: Transaction Publishers; 1990. [Google Scholar]
  • 50.Berg KM, Wilson IB, Li X, Arnsten JH. Comparison of antiretroviral adherence questions. AIDS and behavior. 2012. February;16(2):461–8. 10.1007/s10461-010-9864-z . Pubmed Central PMCID: 3690952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV clinical trials. 2004. Mar-Apr 5(2):74–9. 10.1310/JFXH-G3X2-EYM6-D6UG . [DOI] [PubMed] [Google Scholar]
  • 52.Pellowski JA, Kalichman SC, Finitsis DJ. Reliability and validity of a single-item rating scale to monitor medication adherence for people living with HIV and lower health literacy. HIV clinical trials. 2015. Jan-Feb;16(1):1–9. 10.1179/1528433614Z.0000000004 . Pubmed Central PMCID: 5280070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Thirumurthy H, Siripong N, Vreeman RC, Pop-Eleches C, Habyarimana JP, Sidle JE, et al. Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting. Aids. 2012. November 28;26(18):2399–403. 10.1097/QAD.0b013e328359aa68 . Pubmed Central PMCID: 3606955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Finitsis DJ, Pellowski JA, Huedo-Medina TB, Fox MC, Kalichman SC. Visual analogue scale (VAS) measurement of antiretroviral adherence in people living with HIV (PLWH): a meta-analysis. Journal of behavioral medicine. 2016. December;39(6):1043–55. 10.1007/s10865-016-9770-6 . [DOI] [PubMed] [Google Scholar]
  • 55.Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lester RT, Mills EJ, Smieja M, et al. The Cameroon Mobile Phone SMS (CAMPS) trial: a randomized trial of text messaging versus usual care for adherence to antiretroviral therapy. PloS one. 2012;7(12):e46909. 10.1371/journal.pone.0046909 . Pubmed Central PMCID: 3516507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acq Imm Def. 2004. August 15;36(5):1100–2. 10.1097/00126334-200408150-00014 . [DOI] [PubMed] [Google Scholar]
  • 57.Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of internal medicine. 2000. July 4;133(1):21–30. 10.7326/0003-4819-133-1-200007040-00004 . [DOI] [PubMed] [Google Scholar]
  • 58.Goldstein H, Browne W, Rasbash J. Partitioning Variation in Multilevel Models. Understanding Statistics. 2002. 2002/12/02;1(4):223–31. [Google Scholar]
  • 59.Austin PC, Merlo J. Intermediate and advanced topics in multilevel logistic regression analysis. Statistics in medicine. 2017. September 10;36(20):3257–77. 10.1002/sim.7336 . Pubmed Central PMCID: PMC5575471. Epub 2017/05/26. eng. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Snijders TAB. Power and sample size in multilevel linear models. Encyclopedia of statistics in behavioral science. Chicester (etc.): Wiley; 2005. p. 1570–3. [Google Scholar]
  • 61.McNeish DM, Stapleton LM. The effect of small sample size on two-level model estimates: a review and illustration. Educ Psychol Rev. 2016. Jun;28(2):295–314. WOS:000376253000005. [Google Scholar]
  • 62.Illangasekare S, Tello M, Hutton H, Moore R, Anderson J, Baron J, et al. Clinical and mental health correlates and risk factors for intimate partner violence among HIV-positive women in an inner-city HIV clinic. Women’s health issues: official publication of the Jacobs Institute of Women’s Health. 2012. Nov-Dec;22(6):e563–9. 10.1016/j.whi.2012.07.007 . Pubmed Central PMCID: 3489982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Deyessa N, Berhane Y, Alem A, Ellsberg M, Emmelin M, Hogberg U, et al. Intimate partner violence and depression among women in rural Ethiopia: a cross-sectional study. Clinical practice and epidemiology in mental health: CP & EMH. 2009. April 28;5:8. 10.1186/1745-0179-5-8 . Pubmed Central PMCID: 2689215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Krantz G, Vung ND. 2The role of controlling behaviour in intimate partner violence and its health effects: a population based study from rural Vietnam. BMC public health. 2009. May 14;9. WOS:000266935400003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Kimuna S, Tenkorang EY, Djamba Y. Ethnicity and Intimate Partner Violence in Kenya. Journal of family issues. 2018. August;39(11):2958–81. WOS:000438670200003. English. [Google Scholar]
  • 66.Mukumbang FC, Mwale JC, van Wyk B. Conceptualising the factors affecting retention in care of patients on antiretroviral treatment in Kabwe District, Zambia, using the ecological framework. Aids Res Treat. 2017. WOS:000414796100001. 10.1155/2017/7356362 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: A systematic review and meta-analysis. PLoS medicine. 2016. November;13(11):e1002183. 10.1371/journal.pmed.1002183 . Pubmed Central PMCID: 5127502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Tam M, Amzel A, Phelps BR. Disclosure of HIV serostatus among pregnant and postpartum women in sub-Saharan Africa: a systematic review. Aids Care-Psychological and Socio-Medical Aspects of Aids/Hiv. 2015. April 3;27(4):436–50. WOS:000348662800005. 10.1080/09540121.2014.997662 [DOI] [PubMed] [Google Scholar]
  • 69.Mepham S, Zondi Z, Mbuyazi A, Mkhwanazi N, Newell ML. Challenges in PMTCT antiretroviral adherence in northern KwaZulu-Natal, South Africa. AIDS care. 2011. June;23(6):741–7. 10.1080/09540121.2010.516341 . [DOI] [PubMed] [Google Scholar]
  • 70.Lopez EJ, Jones DL, Villar-Loubet OM, Arheart KL, Weiss SM. Violence, coping, and consistent medication adherence in HIV-positive couples. AIDS education and prevention: official publication of the International Society for AIDS Education. 2010. February;22(1):61–8. 10.1521/aeap.2010.22.1.61 . Pubmed Central PMCID: 3734535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Wilson KS, Wanje G, Yuhas K, Simoni JM, Masese L, Vander Stoep A, et al. A prospective study of intimate partner violence as a risk factor for detectable plasma viral load in HIV-positive women engaged in transactional sex in Mombasa, Kenya. AIDS and behavior. 2016. September;20(9):2065–77. WOS:000381990800022. 10.1007/s10461-016-1420-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Ayuo P, Musick B, Liu H, Braitstein P, Nyandiko W, Otieno-Nyunya B, et al. Frequency and factors associated with adherence to and completion of combination antiretroviral therapy for prevention of mother to child transmission in western Kenya. Journal of the International AIDS Society. 2013;16:17994. 10.7448/IAS.16.1.17994 . Pubmed Central PMCID: 3536941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Swan SC, Snow DL. The development of a theory of women’s use of violence in intimate relationships. Violence against women. 2006. November;12(11):1026–45. WOS:000241242700005. English. 10.1177/1077801206293330 [DOI] [PubMed] [Google Scholar]
  • 74.Downs WR, Rindels B, Atkinson C. Women’s use of physical and nonphysical self-defense strategies during incidents of partner violence. Violence against women. 2007. January;13(1):28–45. WOS:000242973100003. English. 10.1177/1077801206294807 [DOI] [PubMed] [Google Scholar]
  • 75.Denson TF, O’Dean SM, Blake KR, Beames JR. Aggression in Women: Behavior, Brain and Hormones. Front Behav Neurosci. 2018. May 2;12. WOS:000431189600001. English. 10.3389/fnbeh.2018.00081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Fabbiani M, Di Giambenedetto S, Cingolani A, Fanti I, Colafigli M, Tamburrini E, et al. Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. Infectious diseases. 2016. January 2;48(1):48–55. WOS:000373618300006. 10.3109/23744235.2015.1082034 [DOI] [PubMed] [Google Scholar]
  • 77.Campbell JC. Health consequences of intimate partner violence. Lancet. 2002. April 13;359(9314):1331–6. 10.1016/S0140-6736(02)08336-8 . [DOI] [PubMed] [Google Scholar]
  • 78.Cavalin C. WHO multi-country study on women’s wealth and domestic violence against women. Initial results on prevalence, health outcomes and women’s responses. Population. 2010. Oct-Dec;65(4):837–9. WOS:000290926700015. French. [Google Scholar]

Decision Letter 0

Michelle L Munro-Kramer

16 Sep 2020

PONE-D-20-21450

Intimate partner violence a barrier to antiretroviral therapy adherence among HIV positive women: Evidence from government facilities in Kenya

PLOS ONE

Dear Dr. Biomndo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Thank you for your submission. This manuscript has the potential to be a timely contribution to the literature. However, it needs substantial revisions to improve clarity and complete presentation of methods and results. The reviewers have both provided very detailed comments on each section of the manuscript. Below I am providing some more large-scale areas that should be addressed before resubmission:

1) There are numerous grammatical errors and missing words throughout the manuscript that make it difficult to understand what the authors are saying at times. Please consider enlisting the help of a copy editor prior to resubmission.

2) Please ensure consistency of terminology, specifically related to the key concepts in the manuscript (e.g., intimate partner violence (IPV) including physical IPV, sexual IPV, and emotional IPV; antiretroviral therapy). Define terms that may not be well understood (e.g., mixed clinics). Abbreviations should be introduced and then used consistently.

3) Citations need to be consistent per PLOS One format (Vancouver Style) and should be used for each claim that references supporting literature. For example, the introduction cites "IPV is a known risk factor for HIV infection..." without a citation. Also, all tables/figures should be cited in the text.

4) The methods section needs additional details about measures and procedures including: (a) How were the 12 clinics selected (e.g., was it a random sample)?; (b) For inclusion criteria, what were the parameters around "in an intimate relationship"? Did this have to be at the time of the study? At any point in their life?; (c) Were the IPV measurements for lifetime? If so, why was this time frame used when ART adherence focused on the last 30 days?; (d) Is the "recruiter" a trained study staff member or their healthcare provider? Did they have resources available for someone who was actively experiencing IPV and asked for resources? Were participants excluded if there was a safety concern? Were the interviews conducted in private? Were they conducted with paper surveys? Was there an incentive?; (e) How many participants declined participation? What was the reasoning?

5) The results section should be streamlined. First of all, a descriptive/demographic table of the sample is needed. Second, the current tables contain a large amount of information. The authors should consider how to condense this information in an easily digestible way.

6) As noted by Reviewer #1, the conclusion could benefit from a future research or future directions section.

We look forward to receiving your revised manuscript.

Please submit your revised manuscript by Oct 31 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Michelle L. Munro-Kramer, PhD, CNM, FNP-BC

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please state whether you validated the questionnaire prior to testing on study participants.

Please provide details regarding the validation group within the methods section.

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4. Please include a separate caption for each figure in your manuscript.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript has the potential to contribute important information to the literature on women’s ART adherence and IPV. The authors have a large sample size and the findings have extremely important implications on future practices. Several things that should be addressed before this manuscript is ready for publication.

General: Overall, there are many grammatical errors and words that appear to be missing (including in the title). The authors should considering hiring a copy editor to carefully review the manuscript. The authors should also ensure all citations are in a consistent format (e.g., pg. 14 line 241).

Abstract: In the results of the abstract the authors state protective factors but it is unclear if they are protective factors regarding increased ART adherence or IPV.

Introduction:

Overall: The authors state a “gap in the literature” but then cite several studies. It seems that the authors should report conflicting results in the literature rather than a gap. Given the specific populations previous studies focused on, this study adds to the literature by recruiting from multiple types of clinics across locations. I believe this should be further emphasized in the introduction to provide additional rationale of the importance of this study.

Specific:

*The authors state that most studies are conducted in specific regions/cities in Africa, which suggested that the present study would be conducted across sub-Saharan Africa. Discussion on the limitations of location-specific studies should be limited since this study is conducted in Kenya and not across sub-Saharan Africa.

Methods:

Overall: I have some concerns and questions regarding the measures and data analysis.

Specific:

*If IPV influences ART adherence, why were women included only if they had been on ART for at least 6 months? Is it possible that women may not be on ART in the past 6 months because of IPV?

*Adherence was measured in the past 30 days, yet from the description, it appeared that IPV was a lifetime measure. The authors should explain why IPV was not measured in the same timeframe as adherence (or at least more recent—past 3 months).

*The authors should define “mixed clinic” as this is unclear.

*Were participants provided any compensation for participating?

*Was there any missing data? If so, how was it accounted for during analyses? Analyses that included multiple locations often use a nested model to account for differences. Did the authors include clinics in analyses?

Results:

Overall: The tables are somewhat difficult to follow and incorporate a lot of information. Since there are 4 very large tables, the authors should consider a more succinct manor in presenting results.

Specific:

*Figure 1 is not mentioned in the manuscript and it should be referred to as a table rather than a figure.

*A demographics table would be helpful, especially if the authors minimize or combine tables 1 – 4.

*It is unclear what ~ refers to in the tables.

*Many of the variables listed in the tables are not described in the Method/Measures section.

Discussion:

Overall: These results have very important implications for future research and practices. The authors appear to mention these briefly in the Conclusion section. It would be beneficial to provide a “Future Research” or “Future Practices” section in the Discussion that discusses next steps. The Conclusion should briefly summarize the study results and implications.

Reviewer #2: After careful consideration and review of manuscript number PONE-D-20-21450 entitled, “Intimate partner violence a barrier to antiretroviral therapy adherence among HIV positive women: Evidence from government facilities in Kenya”, it is my recommendation for the authors to submit a major revision of the paper. Details are provided below:

Abstract

1. The introduction section is confusing because the authors note that studies on key populations have produced divergent evidence regarding “this association” but it is unclear what “this association” references…intimate partner violence and poor medication adherence or intimate partner violence and virological failure?

2. It’s unclear what “mixed clinics” means.

3. The study design and procedures are unclear in the methods section. I recommend conveying the analysis in a brief, succinct manner to allow room for a sentence or two on the study design and procedures.

4. The study implications are vague. There must be more recommendations than merely integrating IPV screening and counseling services within HIV clinics.

Introduction

1. Although there are no overall IPV prevalence estimates available from sub-Saharan Africa, there have been numerous studies conducted from which prevalence estimates can be cited, within a range.

2. It is inappropriate to claim that IPV is “recognized as a factor behind low uptake and engagement of HIV care” with only one citation provided.

3. There are sentences written without any citations which is unacceptable. For instance on pg. 5, lines 58-60, multiple citations are needed because that sentence references “studies”.

4. Typos and grammatical errors are present and should be corrected.

5. Pg. 5, lines 81-83 presents a sentence that is awkwardly worded; it is difficult to understand the purpose and meaning of the sentence.

6. In one area, “partner violence” is used and in other areas “intimate partner violence” is used. Is this supposed to represent a distinction?

7. The claim is made that “there needs to be an expansive approach that encompasses the diverse population of HIV positive women” but it is unclear what this approach actually is and how this approach serves as the foundation of the paper.

Methods

8. For consistency, once ART has been defined, it is necessary to utilize the acronym throughout the paper. In the methods section, this was not the case.

9. The eligibility criteria does not include participants self-reporting as women; was this not an inclusion criteria?

10. The national IPV prevalence rate was mentioned in the methods section but not included in the introduction section.

11. The term, intimate partner violence or IPV, is loosely used and not consistently used. In some areas the word, “violence” is used. Consistency is necessary. Specifically, “physical violence” should be “physical IPV”, etc.

12. It is unclear what is meant by “mixed clinics”.

13. More details are needed regarding the administration of the survey (e.g., was the location in a private office, computer administered, etc.).

14. How was participation handled for women who were at the clinic with a partner?

15. It is inappropriate to consider the variables in the analysis as “predictors” because the data is cross-sectional in nature, not longitudinal.

Results

16. The traditional “Table 1” is missing. This table typically provides descriptive statistics to describe the sample.

17. Figure 1 is included but never referred to in the text of the manuscript.

18. Again, in stating the different types of violence, it should be specified that these types of violence are IPV (emotional IPV, sexual IPV).

19. The table titles are misleading and need to account for both the primary independent variable and dependent variable.

Discussion

20. The authors need to be clear that the discussion points are centered around “lifetime” IPV rather than just stating “prevalence of IPV” – this should be “prevalence of lifetime IPV”.

21. The authors make an incorrect declarative statement (pg. 15, line 255). The study findings can only corroborate studies that document an association between IPV and poor adherence to ARV medication, not the association between IPV and poor uptake of ARV medication.

22. Pg. 16, line 287-290 – This sentence is grammatically incorrect.

23. The implications of the study findings are general and do not provide significant details on how the finding could inform practice and policy. Additionally, there is lack of specificity in terms of future research directions resulting from the current study findings.

24. Limitations should be discussed regarding the time anchor for the measure, lifetime IPV. Recent IPV may have been a better indicator as it relates to impeding ART adherence.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Apr 21;16(4):e0249813. doi: 10.1371/journal.pone.0249813.r002

Author response to Decision Letter 0


31 Oct 2020

Editor’s comments

1) There are numerous grammatical errors and missing words throughout the manuscript that make it

difficult to understand what the authors are saying at times. Please consider enlisting the help of a copy editor prior to resubmission.

Thank you for the feedback. Reviewers #1 and #2 also commented on the grammatical errors and typos. We have therefore changed the title to read ‘Intimate partner violence is a barrier to antiretroviral therapy adherence among HIV-positive women: Evidence from government facilities in Kenya’. Furthermore, we have rectified the typos and grammatical errors within the manuscript and hired a professional copy editor to review the final draft.

2) Please ensure consistency of terminology, specifically related to the key concepts in the manuscript

(e.g., intimate partner violence (IPV) including physical IPV, sexual IPV, and emotional IPV; antiretroviral therapy). Define terms that may not be well understood (e.g., mixed clinics). Abbreviations should be introduced and then used consistently.

We thank you for this correction. Reviewers #1 and #2 also commented that the term ‘mixed clinics’ was unclear. Reviewer #2 pointed out that the term ‘IPV’ was loosely and inconsistently used, that consistency was necessary, and that the different types of violence should be specified as physical IPV, emotional IPV, etc. We have revised the manuscript to clearly and consistently identify the forms of violence as IPV and to consistently use the term IPV. We have rewritten the part of the abstract that mentioned ‘mixed clinics’ (Pg. 2 line 28). Within the methods section, we have clarified in Pg. 8 lines 145 and 146 that ‘mixed clinics refer to non-specialized clinics where female and male HIV-positive adults are reviewed and given medication refills.

3) Citations need to be consistent per PLOS One format (Vancouver Style) and should be used for

each claim that references supporting literature. For example, the introduction cites "IPV is a known risk factor for HIV infection..." without a citation. Also, all tables/figures should be cited in the text.

Thank you for pointing out this oversight. Reviewers #1 and #2 also commented on citation. Specifically, in the previous manuscript, Reviewer #1 noted that all citations should be in a consistent format and gave the example of Pg. 14 line 241, which was not consistent with the format. Reviewer #2 pointed out that it was inappropriate to claim that IPV is “recognised as a factor behind low uptake and engagement of HIV care” and provide only one citation. Additionally, some sentences (e.g. Pg. 5 lines 58-60) were missing citations. In the revised manuscript we have ensured that all references are appropriately cited (i.e. Pg. 15 line 259). We have added six citations to support the introductory statement that ‘Intimate Partner Violence (IPV) is recognised as a factor behind low uptake and engagement of HIV management services’, and added citations in Pg. 4 lines 58 and 59 for the studies we referred to. Moreover, regarding the claim that ‘IPV is a risk factor for HIV infection among women....’ (Pg. 4 line 59), we have added two citations and separately referenced lines 60-62, which we had previously erroneously combined into one citation.

For the tables and figures, we have included the traditional Table 1 as advised and created a new table that we believe gives a concise and clear summary of the logistic regression analysis results. We have also confirmed that all relevant tables are mentioned in the texts.

4) The methods section needs additional details about measures and procedures including:

(a) How were the 12 clinics selected (e.g., was it a random sample)?

Within the study design and setting section, we have added a sentence explaining that the 12 clinics were selected based on the number of active HIV-positive women on ART they, and also to represent the different counties (regions) in western Kenya. Consequently, we included large clinics with high numbers of women on ART in the different counties. Additionally, smaller clinics were selected to have representation from less populous communities. We have rewritten the information in the methods section (Pg.5 lines 93–97) to clarify this.

(b) For inclusion criteria, what were the parameters around "in an intimate relationship"? Did this have to be at the time of the study? At any point in their life?

(c) Were the IPV measurements for lifetime? If so, why was this time frame used when ART adherence focused on the last 30 days?

We appreciate the detailed feedback and we acknowledge that the study’s definition and measurement of IPV was somewhat unclear in the previous manuscript. Reviewer 1# also commented that, while adherence was measured over the past 30 days, the description suggested that IPV was a lifetime measure. Reviewer #1 stated that we should explain why IPV was not measured in the same timeframe as adherence (or at least more recently, such as the past 3 months). Since these comments are related, we decided to combine them and offer a comprehensive response.

Our study focuses on the current relationship and the occurrence of IPV within the relationship’s lifetime. We have clarified this by including within the data collection section the description of the IPV measurement and a sentence defining an intimate partner as someone to whom the woman was currently married (whether in a monogamous or polygamous marriage) or a person with whom she was in a romantic relationship (Pg. 6 Lines 118 and 119). We have also included the words ‘current intimate partner’ and ‘current relationship’ in the abstract, results, and discussion sections whenever we refer to the partner or relationship.

We chose to use a relationship-specific timeframe for IPV exposure and ART adherence in the 30 days prior to the survey, because our interest was investigating whether living in an environment where IPV occurs (whether past or ongoing) affects a woman’s ability to adhere to treatment. We hypothesise that there is a potential link. Our reasoning is that, although a specific IPV incident may not affect medication adherence, the impact of living in such a setting is what influences the woman’s ability to maintain optimal ART adherence.

(d) Is the "recruiter" a trained study staff member or their healthcare provider? Did they have resources available for someone who was actively experiencing IPV and asked for resources? Were participants excluded if there was a safety concern? Were the interviews conducted in private? Were they conducted with paper surveys? Was there an incentive?

Reviewer #1 also asked whether the women were offered any compensation for participating. We have added more information on the recruiters, the survey administration process, and the compensation within the procedure section. The ‘recruiters’ were the women’s regular healthcare providers – i.e. clinical officers and nurses who provide and supervise ART at the clinics. The healthcare providers were trained on the aims of the study, the recruitment process, and questionnaire administration. A list of in-house resources (social workers and, where available, a legal aid office) and external resources (government authorities, non-governmental organisations in the area that work in gender-based violence prevention/women’s empowerment) was compiled and offered to women who reported exposure to IPV.

The survey was conducted right after the woman’s routine clinical check-up; therefore, it took place in the same examination room. Although this was very convenient and practical, unfortunately, it meant that if the examination room was shared, the healthcare providers had to ensure some form of privacy when administering the questionnaire. They did so either by asking their fellow healthcare provider to temporarily leave the room or by creating physical distance by moving their desks or dividing the room with a curtain. If the woman was accompanied by another adult or a child who was old enough to understand the conversation, the person/child was politely asked to leave the room before the questionnaire was administered. Women who participated in the survey were compensated for their time and effort in form of cash, which was referred to as ‘transport money’. This was only mentioned and given after the woman completed the questionnaire. This information has been added within the procedure section.

In the data collection section, we have added a sentence clarifying that the questionnaire was in paper form (Pg. 7 lines 142 and 143).

(e) How many participants declined participation? What was the reasoning?

Thank you for raising this question. In the discussion section, we have added information stating that, despite anticipating some hesitance from the women, all of the healthcare providers reported that the women they approached willingly and openly discussed their IPV experience. We have also included the reasons that we think the women were receptive to the survey (Pg. 14 Lines 244 -248). Although some healthcare providers did require more time to recruit women, this was due to not having enough women who fit the criteria, rather than the women declining to participate.

5) The results section should be streamlined. First of all, a descriptive/demographic table of the sample

is needed. Second, the current tables contain a large amount of information. The authors should consider how to condense this information in an easily digestible way.

Thank you for this feedback. We have added Table 1, which contains descriptive information about the sample. The previous tables were certainly large and information-heavy. Therefore, we have developed a single table (Table 2) that combines the previous four models in a concise way that is easier to follow. We decided not to report the results of the single regression analyses within an extra table; instead, we focus on the full regression models, which are more informative.

Within Table 2, Pseudo R2 values are reported for transparency even though the aim of our model is to explore the association between the independent variables and the dependent variable, and not to predict the dependent variable [1, 2]. Nevertheless, the arguably low Pseudo R2 values were not surprising to us since we expected that there are other variables that affect ART that were not measured in our survey [3].

6) As noted by Reviewer #1, the conclusion could benefit from a future research or future directions

section.

Reviewer #1 commented that it would be beneficial to provide a ‘Future Research’ or ‘Future Practices’ section that discusses next steps. The Conclusion should briefly summarise the study results and implications. We agreed that the discussion and conclusion could be improved and have rewritten them to expound more on the implications of our study; we have specified the practical steps that can be taken and suggested future research. Specifically, we have added a ‘Future practices’ segment within the discussion section (Pg. 18 line 351) that expounds on the practicality of integrating basic IPV screening and counselling within HIV clinics and the role that healthcare providers can play in this regard. We also indicate the need for strategies at the societal level to create awareness on the negative effects of IPV, the laws that protect against it, and the existing resources that are available for women exposed to IPV. To conclude, we have expressed the need for more evidence on the direct and indirect benefits of integrating IPV screening and counselling for women in healthcare settings. We have called on future researchers to target vulnerable groups (e.g. women who drop out of ART programs) and to produce more evidence on the negative effects of controlling behaviour.

Reviewer #1

Abstract

In the results of the abstract the authors state protective factors but it is unclear if they are protective factors regarding increased ART adherence or IPV.

Noted. We have rewritten the sentence to make it clear that the protective factors regard increased ART adherence (Pg. 2 line 39).

Introduction:

Overall: The authors state a “gap in the literature” but then cite several studies. It seems that the authors should report conflicting results in the literature rather than a gap. Given the specific populations previous studies focused on, this study adds to the literature by recruiting from multiple types of clinics across locations. I believe this should be further emphasized in the introduction to provide additional rationale of the importance of this study.

This is true. Our intention was to emphasise that the studies that have aimed to fill this gap in the literature by focusing on specific subsets of women have produced contrasting and inconclusive evidence. Therefore, our study aims to contribute by adding evidence from a broad group of women. We now realise that area was not well-written in the previous manuscript. We have revised parts of the introduction section to make this point more clearly (Pg. 5 lines 74-82).

Specific:

*The authors state that most studies are conducted in specific regions/cities in Africa, which suggested that the present study would be conducted across sub-Saharan Africa. Discussion on the limitations of location-specific studies should be limited since this study is conducted in Kenya and not across sub-Saharan Africa.

By mentioning specific locations in our paper, our intention was to highlight that there are studies from other sub-Saharan African countries which may be comparable to our setting and population in Kenya. We did not intend to imply that the study location could be a limiting factor or that our study was conducted in several locations. Any discussion or comparison to a specific study has focused on the sample population (e.g. pregnant and postpartum women, transactional sex workers) or the method of measuring ART adherence (cumulative ART adherence and cut-off points). However, we now see how highlighting specific locations could have a different effect than we anticipated; therefore, we have limited this in the revised manuscript.

Methods:

Overall: I have some concerns and questions regarding the measures and data analysis.

Specific:

*If IPV influences ART adherence, why were women included only if they had been on ART for at least 6 months? Is it possible that women may not be on ART in the past 6 months because of IPV?

We realized that the wording we used to explain this criteria was misleading, and we have rewritten it in Pg.6 lines 100–103. The six-month limit refers to the length of time since initiation of ART – not to the length of time that the women had actively been on ART prior to the survey. Therefore, it did not matter whether or for how long the woman had been off ART prior to the study. They were included as long as the onset of ART was more than six months prior to the survey. Our outcome of interest was ART adherence. Because we hypothesise that some factors affecting adherence are related to the initiation stages of ART, we tried to minimise these factors by capturing women who may have been accustomed to the ART routine.

*Was there any missing data? If so, how was it accounted for during analyses? Analyses that included multiple locations often use a nested model to account for differences. Did the authors include clinics in analyses?

We have added a brief paragraph in the data analysis section ( from Pg. 9 line 182) explaining that a missing value analysis was performed and none of the variables had more than 5% missing values; we also did not find any systematic relationships between the missing values. Regarding the nested structure of our data, we have added on Pg. 9 line 190- 193 that we decided against a multilevel modelling procedure because, with as few as 12 clusters, fixed-effect estimates associated with level-2 predictors could have been severely biased.

Results:

Overall: The tables are somewhat difficult to follow and incorporate a lot of information. Since there are 4 very large tables, the authors should consider a more succinct manor in presenting results.

Specific:

*Figure 1 is not mentioned in the manuscript and it should be referred to as a table rather than a figure

*A demographics table would be helpful, especially if the authors minimize or combine tables 1 – 4.

Thank you for this feedback. We have made major revisions to the tables and figures, as suggested. We developed Table 1, which contains demographic information on the participants. We have combined the previous tables (Tables 1–4) into a single table (Table 2).

We removed the table containing information on the clinics (previously erroneously identified as Figure 1) and offered it as extra supplementary information, since it does not directly relate to the results and only serves as extra information. Additionally, we deleted Figure 2 since the information that was presented is now available in Table 1 and within the text in the results section.

*It is unclear what ~ refers to in the tables.

Noted. We have deleted the symbol since we realised that the information was clear without it.

*Many of the variables listed in the tables are not described in the Method/Measures section.

We apologise for this oversight. On Pg. 7 line 139–142 we have included all of the variables that are later presented in the tables

Reviewer #2

After careful consideration and review of manuscript number PONE-D-20-21450 entitled, “Intimate partner violence a barrier to antiretroviral therapy adherence among HIV positive women: Evidence from government facilities in Kenya”, it is my recommendation for the authors to submit a major revision of the paper. Details are provided below:

Abstract

1. The introduction section is confusing because the authors note that studies on key populations have produced divergent evidence regarding “this association” but it is unclear what “this association” references…intimate partner violence and poor medication adherence or intimate partner violence and virological failure?

Noted. By ‘this association’ we were referring to IPV’s link to adverse clinical outcomes. However, since our paper focuses on poor ART adherence, we have decided to rewrite the statement to specify the association between IPV and poor ART adherence (Pg. 2 line 23 -25).

2. (This comment has already been responded to under Editor’s comment #2)

3. The study design and procedures are unclear in the methods section. I recommend conveying the analysis in a brief, succinct manner to allow room for a sentence or two on the study design and procedures.

Noted. We have rewritten the section to read ‘We sampled 408 HIV-positive women receiving free ART from different types of HIV clinics at government health facilities, assessing for IPV exposure by a current partner, ART adherence rate, and other factors that affect ART adherence (e.g. education, disclosure). ART adherence rates were measured using the Visual Analogue Scale (VAS); responses were dichotomised at a ≥95% cut-off. Multiple logistic regression models assessed the association between the independent variables and ART adherence.

4. The study implications are vague. There must be more recommendations than merely integrating IPV screening and counselling services within HIV clinics.

Thank you for highlighting this. We have revised the conclusion section to read ‘IPV is associated with suboptimal ART adherence rates among a broad group of HIV-positive women. ART programs should consider incorporating basic IPV interventions into regular clinic services and using healthcare providers as information and navigation points for women exposed to IPV.’

Introduction

1. Although there are no overall IPV prevalence estimates available from sub-Saharan Africa, there have been numerous studies conducted from which prevalence estimates can be cited, within a range.

Thank you for this suggestion. We were able to find some estimates, which we have included in Pg. 4 lines 52 and 53.

2. and 3. (These comments on citation have already been addressed under the Editor’s comment #3)

4. (This comment on typos and grammatical errors has been addressed under Editor’s comment #1)

5. Pg. 5, lines 81-83 presents a sentence that is awkwardly worded; it is difficult to understand the purpose and meaning of the sentence.

Noted. We realise our mistake and have rewritten the sentence to read ‘So far, the evidence from sub-Saharan Africa has been based on research among key populations, such as transactional sex workers and women at Prevention of Mother-to-Child Transmission (PMTCT) clinics (Pg. 5 lines 77–79).

6. In one area, “partner violence” is used and in other areas “intimate partner violence” is used. Is this supposed to represent a distinction?

No, the intent was not to make any distinction. We acknowledge this mistake and have corrected it by consistently mentioning IPV whenever we talk about violence.

7. The claim is made that “there needs to be an expansive approach that encompasses the diverse population of HIV positive women” but it is unclear what this approach actually is and how this approach serves as the foundation of the paper.

Thank you for pointing this out. To clarify what the approach is, we have revised this claim on Pg. 5 line 79–82 to read ‘However, to determine whether IPV exerts an overarching influence on ART adherence, the association between both variables must be explored among a broader sample of HIV-positive women with diverse socioeconomic characteristics who are receiving the available standard ART from different types of HIV clinics.’

Methods

8. For consistency, once ART has been defined, it is necessary to utilize the acronym throughout the paper. In the methods section, this was not the case.

Noted. We have revised the manuscript and ensured that the abbreviation is used consistently throughout.

9. The eligibility criteria does not include participants self-reporting as women; was this not an inclusion criteria?

The women were recruited from patient lists which are developed from the official medical records. The patient lists are a list of the clients who have clinic appointments on that day. The recruiters used the patient lists to randomly select participants who, based on their official medical records which the clients filled in during their first clinic encounter, are categorised as ‘female’. Since this categorisation was predetermined by how the participant self-identifies in their official medical records, we did not see the need to consider it as an extra criteria. Nevertheless, in the questionnaire, we were conscious to use the term ’partner’ when gathering information about the relationship with the intimate partner, and ‘husband/partner’ when measuring exposure to IPV.

10. The national IPV prevalence rate was mentioned in the methods section but not included in the introduction section.

Thank you for highlighting this omission. We have included the national IPV rate in the introduction section (Pg. 4 lines 55 and 56).

11. (This comment on inconsistent use of the term IPV has been addressed under Editor’s comment #2)

12. (This comment on mixed clinics has been addressed under Editor’s comment #2)

13. More details are needed regarding the administration of the survey (e.g., was the location in a private office, computer administered, etc.).

14. How was participation handled for women who were at the clinic with a partner?

Added. We have added in Pg. 7 lines 142 and 143 a sentence explaining that the questionnaire was in paper form. Furthermore, within the procedure section (from Pg.8 line 155), we have included more information on where and how the questionnaire was administered, as well as the process. Specifically, we have explained that the survey was administered in the regular examination room by the healthcare provider immediately after the routine clinic visit was completed. Although very practical, the challenge with this set-up was that the healthcare provider had to ensure maximum possible privacy. We have also stated that, in cases where the woman was accompanied by another person or a child who was old enough to understand the questions, the person or child was politely asked to leave the room.

15. It is inappropriate to consider the variables in the analysis as “predictors” because the data is cross-sectional in nature, not longitudinal.

Noted. We reviewed the manuscript and have now limited the use of the word ‘predictor’ to only describe the relationship between two variables in the process of statistical modelling. This is in line with OECD’s definition of the term ‘prediction’ within statistical contexts[4]. When inferring to the real world, we have used the term ‘independent variable’. We regret any previous oversight in this regard.

Results

16. The traditional “Table 1” is missing. This table typically provides descriptive statistics to describe the sample.

Added. We have developed Table 1, which contains demographic information for the participants.

17. Figure 1 is included but never referred to in the text of the manuscript.

We removed the table containing information on the clinics (previously erroneously identified as Figure 1) and offered it as extra supplementary information since it does not directly relate to the results and only serves as extra information.

18. (This comment has been responded to under Editor’s comment #2)

19. The table titles are misleading and need to account for both the primary independent variable and dependent variable.

Thank you for highlighting this. We have corrected this in Tables 1 and 2, which we have developed to summarise the results.

Discussion

20. The authors need to be clear that the discussion points are centered around “lifetime” IPV rather than just stating “prevalence of IPV” – this should be “prevalence of lifetime IPV”.

Agreed. We needed to be clearer on the definition of the prevalence of IPV. We have rewritten the subtitle to read ‘Prevalence of IPV within the current relationship’ on Pg. 10 line 199 and Pg.14 line 236.

21. The authors make an incorrect declarative statement (pg. 15, line 255). The study findings can only corroborate studies that document an association between IPV and poor adherence to ARV medication, not the association between IPV and poor uptake of ARV medication.

This is correct and we regret this error. We have corrected the statement to read that the finding corroborates studies that link IPV to poor adherence to ARV therapy among women (Pg. 15 line 276 and 277).

22. Pg. 16, line 287-290 – This sentence is grammatically incorrect.

Noted. After reassessing the sentence, we agreed that deleting it would not alter the point we were aiming to make. We deleted the sentence and took the opportunity to restructure the argument about the effects of controlling behaviour (Pg. 17 line 308- 314).

23. The implications of the study findings are general and do not provide significant details on how the finding could inform practice and policy. Additionally, there is lack of specificity in terms of future research directions resulting from the current study findings.

We agree that the conclusion could be improved and we have added a section on ‘future practices’ within the discussion section (Pg. 18 line 351), which expounds on the implications of our study and specifies the practical steps that can be taken. Additionally, we completely rewrote the conclusion section to include suggestions on future research (Pg. 19 lines 372).

24. Limitations should be discussed regarding the time anchor for the measure, lifetime IPV. Recent IPV may have been a better indicator as it relates to impeding ART adherence.

Thank you for pointing this out. We took the comment into consideration and included in the limitation section (Pg. 18 from line 337) that, although this could have limited our ability to associate IPV to suboptimal ART adherence, the reason for measuring exposure to IPV within the current intimate relationship (regardless of when it occurred) and comparing it to the 30-day self-reported ART adherence was that our aim was to investigate the impact that past or ongoing IPV within the relationship had on ART adherence. Our rationale is that specific IPV incidents may not affect medication adherence; rather, living in an environment in which IPV occurs is what influences the woman’s ability to maintain optimal ART adherence.

Journal Requirements

1) Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

2) Please state whether you validated the questionnaire prior to testing on study participants. Please provide details regarding the validation group within the methods section.

3) We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly.

We have uploaded our data set to Zenodo and it is available under the following DOI: 10.5281/zenodo.4135394.

4) Please include a separate caption for each figure in your manuscript.

We apologise for the oversight. We have included the necessary captions for the tables (we no longer have any figures).

References

1. Forst J. Regression analysis : An intuitive guide for using and interpreting linear models. Pennsylvania, United States: Statistics By Jim Publishing; 2019.

2. Editor MB. The Minitab Blog [Internet]. Minitab, editor. State College2013. [cited 2019]. Available from: https://blog.minitab.com/blog/adventures-in-statistics-2/regression-analysis-how-do-i-interpret-r-squared-and-assess-the-goodness-of-fit.

3. Giselmar A. J. Hemmert LMS, Jan Wieseke, and Heiko Schimmelpfennig. Log-likelihood-based Pseudo-R2 in logistic regression: Deriving sample-sensitive benchmarks. Sociol Method Res. 2018;47(3).

4. Marriott FHC. A Dictionary of Statistical Terms. 5th ed. Harlow, Essex: Longman Scientific & Technical; 1990. 223 p.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Michelle L Munro-Kramer

11 Jan 2021

PONE-D-20-21450R1

Intimate partner violence is a barrier to antiretroviral therapy adherence among HIV-positive women: Evidence from government facilities in Kenya

PLOS ONE

Dear Dr. Biomndo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Thank you for the time and attention you put into this resubmission. As noted by both reviewers, this submission is greatly improved. There are still a few areas that could be addressed as outlined by Reviewer #1 and Reviewer #2 (who was a new reviewer and noted that a paragraph on the conceptual framing of the study, including why the covariates were selected is needed). Both reviewers have provided very detailed feedback which will continue to improve this manuscript. We look forward to receiving your revision.

Please submit your revised manuscript by Feb 25 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Michelle L. Munro-Kramer, PhD, CNM, FNP-BC

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: (No Response)

Reviewer #4: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Partly

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: I Don't Know

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: This manuscript is an interesting foray into an understudied population. The authors should be commended for their work from the previous draft- it seems much improved. However, there are some methodological questions and framing issues that need attention before the manuscript should be considered for publication.

Line 71: Please expound upon the proposed mechanisms in the literature between IPV and HIV management service uptake

There is a lack of theoretical or conceptual underpinnings here- *why* do the authors proposed IPV being a barrier to ARV uptake? This is not a new concept, so existing literature and concepts just need to be brought into this section and tailored for the study context. The authors briefly mention this in Line 285, but this should be corroboration of an earlier theory-driven hypothesis

Line 122: Did the authors alter the DHS questionnaire to focus on relationship-length violence? Since the DHS measures only past-year and lifetime, alterations must have been made to focus on violence ever being perpetrated by the current partner? If so, this is an interesting innovation and should be discussed further.

Methods Note: The other aspects of the model are not discussed- why did the authors choose the predictor variables they did? What is the theory/conceptual model driving these models?

I am concerned with the “woman is violent” covariate. This implies a bidirectionality of IPV that is not theoretically or conceptually consistent with violence in this context. I recommend removing it or strongly justifying it in the (yet nonexistent) paragraph explaining the other model covariates.

Line 166: Can the authors provide a citation or reference to whether 100 shillings is standard compensation for such a survey? Non-Kenyan audiences may call into the question the coerciveness of this amount without this context

Line 179: “virological” is not a word- should be “viral” suppression

Line 192: Despite the potential bias of small numbers of second-level units, the authors should have performed a sensitivity analysis to determine if results varied widely using a two-level model. The authors should have at least included clinic as a fixed effect at level 1 if not using multilevel modeling to control for the effect of sampling site

Line 210: I assume the authors did not try to fit logistic regression models with such small cell sizes as in Age<20 (n=1). Categories of the predictor variables should be reported in the way they were modeled in the final table

Line 228: Why are variables modeled differently in Table 1 vs Table 2 (e.g. Age modeled as continuous in table 2 but categorical in table 1?). These should be consistent.

Line 214: I recommend using positive verbiage here- i.e. “physical, sexual, and any type of IPV remained significant”

Line 246: citations needed here for the Kenyan context

Line 372: I feel the conclusion needs work. What are the final lessons learned and next steps for this line of inquiry- additional thoughts from the researchers would be welcome here.

Reviewer #4: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

Reviewer #4: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Plos_adherence.pdf

PLoS One. 2021 Apr 21;16(4):e0249813. doi: 10.1371/journal.pone.0249813.r004

Author response to Decision Letter 1


8 Feb 2021

Reviewer’s comments

This manuscript is an interesting foray into an understudied population. The authors should be commended for their work from the previous draft- it seems much improved. However, there are some methodological questions and framing issues that need attention before the manuscript should be considered for publication.

1a) Line 71: Please expound upon the proposed mechanisms in the literature between IPV and HIV management service uptake.

1b) There is a lack of theoretical or conceptual underpinnings here- *why* do the authors proposed IPV being a barrier to ARV uptake? This is not a new concept, so existing literature and concepts just need to be brought into this section and tailored for the study context. The authors briefly mention this in Line 285, but this should be corroboration of an earlier theory-driven hypothesis.

1c) I miss a description of why there might be an association between IPV and adherence in the Introduction.

Thank you for the comments. We decided to combine the three comments because we believe they stem from the missing conceptual framework which we should have included.

Along the HIV care cascade (i.e. HIV infection, diagnosis, linking to care, retention in care, initiation of ART, and achieving viral suppression), there are several points at which IPV is said to interfere with interventions being successful. Different studies have tried to establish and quantify this interference at different steps of the cascade. For our study, we focus on the last step which is achieving viral suppression through ART adherence. However, we briefly introduce the other cascade points within our introduction section as background information on the relationship between IPV and ART adherence.

It is true that we failed to include the conceptual framework which could have made this clearer. Therefore in the revised manuscript we included the conceptual framework on ART adherence which guided our research study on Pg. 4 line 70 -73. That is, ‘Alongside treatment regime, provider-patient relationship, clinic setting, and disease characteristics, the conceptual framework on ART adherence identifies sociodemographic drivers as having the potential to influence a patient’s level of medical adherence. Particularly, that there are socio-cultural and interpersonal factors (i.e. partner interference) that physically or psychologically undermine a woman’s ability or motivation to adhere to ART.

2a) Line 122: Did the authors alter the DHS questionnaire to focus on relationship-length violence? Since the DHS measures only past-year and lifetime, alterations must have been made to focus on violence ever being perpetrated by the current partner? If so, this is an interesting innovation and should be discussed further.

2b) The authors use self-reported lifetime IPV restricted to the current partner. Since they first write that they use the DHS IPV module and then (correctly) state that it measures IPV by current and former partners (page 6-7), the claim that the authors focus on lifetime IPV of the ongoing relationship is confusing. Either the claim is wrong or the authors have modified the DHS IPV module. If they have modified it, this should be clearly stated.

Our study focused on relationship-specific IPV and we did this by recruiting only the women who were currently in an intimate partnership (either married or in a relationship). The DHS questions on IPV are framed as ‘Did your (last) husband/partner ever..’ to capture IPV by current or former partner. To make the questions fit to our focus, we removed the word ‘last’ so that our questions read ‘Did your husband/partner ever..’. We apologise for not clarifying this earlier and we have added a few lines in Pg. 7 from line 129 explaining this.

3) Methods Note: The other aspects of the model are not discussed- why did the authors choose the predictor variables they did? What is the theory/conceptual model driving these models?

Thank you for pointing this out. Within the data collection section, we have rewritten the sentence on the independent variables to state why they were used (Pg. 7 from line 146). We hope that this, together with the now added theoretical framework, will make it easier for the reader to understand why we included these covariates.

4) I am concerned with the “woman is violent” covariate. This implies a bidirectionality of IPV that is not theoretically or conceptually consistent with violence in this context. I recommend removing it or strongly justifying it in the (yet nonexistent) paragraph explaining the other model covariates.

Thank you for the comment. This covariate was added because it is an aspect which the DHS IPV questionnaire measures. Since we believe there was a hypothesis behind adding it in the domestic violence module, were interested in investigating whether it would influence our results. From the results, the variable does not add any strong argument for or against our hypothesis. It also does not stand out as a strong point of discussion. Nevertheless, for the sake of transparency we presented it because it was significant in the bivariate analyses and in some points of the logistic regression.

5). Line 166: Can the authors provide a citation or reference to whether 100 shillings is standard compensation for such a survey? Non-Kenyan audiences may call into the question the coerciveness of this amount without this context.

To the best of our knowledge there is no standard compensation for such a survey that we can reference. The research was paid for using limited private funds. After consulting with the AMPATH leadership and the healthcare workers, we agreed that KSh 100 (a little less than 1€ at the time) which was all we could afford, was better than giving nothing.

With regard to the possible coerciveness of this amount, we describe in the procedure section (Pg. 8 line 166 -174) that consent to participate in the study was sought through explaining the purpose of the study and reassuring the women that participation or non-participation was purely voluntary and would not affect their access to ART. The compensation was offered only after consent was given and the women had completed the questionnaire. Moreover, in terms of purchasing power KSh 100 is unfortunately very low. We would have wished to offer the participants more, had we had proper funding.

6) Line 179: “virological” is not a word- should be “viral” suppression

To the best of our knowledge, virological suppression and viral suppression can be used interchangeably. We also decided to use “virological suppression” as it was already used in other papers published in PlosOne and PlosMedicine, most recently Plymoth M. et al [1] and Hermans, L.E. et al [2].However, we are happy to use the term ‘viral suppression’ instead if it fits better to the discourse of PlosOne.

7) Line 192: Despite the potential bias of small numbers of second-level units, the authors should have performed a sensitivity analysis to determine if results varied widely using a two-level model. The authors should have at least included clinic as a fixed effect at level 1 if not using multilevel modelling to control for the effect of sampling site

Thank you for highlighting this. To provide the reader with the additional information we have added more details on the analyses we conducted before reaching the decision on our final model on Pg. 10 from line 200. That is, we decided against a multilevel modelling procedure due to the comparatively low intraclass correlation coefficient of ICC=.15 which we derived from an unconditional multilevel logistic regression model. Additionally, with as few as 12 clusters, fixed-effect estimates associated with level-2 predictors could have been severely biased. Adding clinic as an independent variable as part of our sensitivity analysis revealed differences among the clinics but there were no significant changes in the respective model parameter estimates from previous models.

8) Since data on IPV during the last 12 months are available, which in my view would have been more suitable for the study than lifetime IPV, the authors should at least comment on how the results are altered if they are used.

Noted. Within the data analysis section (Pg. 9 line 184), we have now added a short paragraph explaining that we also ran a second analysis considering only exposure to IPV in the last 12 months. The results of this second analysis have been added in the results section (Pg. 11 line 223-225, and Pg. 12 line 261-267). The findings mirror those of the relationship-specific IPV analysis; i.e. experiencing IPV reduces the odds of achieving optimal ART adherence, while education level and having an HIV-positive partner increased the odds of achieving optimal ART adherence. This further strengthens our rationale that specific IPV incidents may not affect medication adherence, but living in an environment in which IPV occurs does.

9a) Line 210: I assume the authors did not try to fit logistic regression models with such small cell sizes as in Age<20 (n=1). Categories of the predictor variables should be reported in the way they were modelled in the final table.

9b) Line 228: Why are variables modelled differently in Table 1 vs Table 2 (e.g. Age modelled as continuous in table 2 but categorical in table 1?). These should be consistent.

9c) What does marital status, monogamy, polygamy in Table 1 mean? The classification is unclear

Thank you for bringing these points to our attention. We apologise for the oversight and have changed them accordingly (Pg. 11)

10) The authors write as if unadjusted results are reported, see p. 11 lin3-4. However, they are not reported.

Thank you for pointing this out. We had presented both the unadjusted and adjusted results in our earlier manuscripts, hence the tone in reporting and the references. We have now revised this to fit to what is actually presented in the current manuscript (Pg. 12 from line 251).

11) Line 214: I recommend using positive verbiage here- i.e. “physical, sexual, and any type of IPV remained significant”

Noted. We changed the text following the reviewer’s suggestion (Pg. 12 line 252-253).

12) Line 246: citations needed here for the Kenyan context

We have added the relevant citations (Pg. 14. Line 289).

13) Typo, p.19, line 6. on should be of.

Noted. We decided to change the statement to ‘A review on programs in sub-Saharan Africa which have implemented IPV screening and counselling services in healthcare settings, reported that the interventions were positively received by both healthcare providers and clients’ (Pg. 19 line 412).

14a) Line 372: I feel the conclusion needs work. What are the final lessons learned and next steps for this line of inquiry- additional thoughts from the researchers would be welcome here.

14b) “ART programs should consider incorporating basic IPV interventions into regular clinic services and using healthcare providers as information and navigation points for women exposed to IPV” does not follow from the findings. Such a conclusion should be based on evidence of a casual effect of IPV on ART adherence. An association does not have to be due to the impact of IPV on adherence. For example, women who end up with violent men might be different from others in ways not captured by the control variables, making them care less about their health. Moreover, violent men might have characteristics that influence their partners’ adherence. One example is that they are likely to be less faithful and less caring. Thus, a program that reduces IPV might not improve adherence. Although it seems reasonable that IPV actually has a causal effect on adherence, the conclusion drawn from the study should be modified.

Noted. We decided to combine the two points because we believe they are related.

It is true that our findings show only a negative association and not a causal effect of IPV on ART adherence. From a researcher’s point of view, we consider this a limitation (as stated in the limitation section Pg. 18 line 389). However, from a practitioner’s point of view we still stand by our recommendation to consider introducing brief IPV screening and counselling at clinic level as a preventive measure. As existing literature on ART has established, the factors that influence ART adherence are diverse [3-9]. Therefore, it is true that in the end, any reduction in the effects of IPV may not result in improved ART adherence. Nonetheless, since our findings tell us that exposure to IPV could create a group that is vulnerable to suboptimal ART adherence, we recommend identifying these women who need extra monitoring and support. At the same time, given the high prevalence of IPV and knowing that, in general, IPV has negative effects on women’s health, an intervention would be good for the HIV-positive woman’s overall quality of life. As it stands, the jury is still out on whether IPV screening and counselling at clinical level has direct or indirect benefits on women’s health. We request future researcher to share their findings.

We have adjusted the future practices and conclusion section to reflect these sentiments (Pg. 19 line 398).

15) A related issue is the consequences of IPV on HIV-infections. The authors describe these in the first two paragraphs of the paper and refer to several papers. However, they miss some important references and the fact that recent evidence indicates that there might not be a causal effect of IPV on HIV-infections among women in Sub-Saharan Africa. Women who live with violent men are primarily infected because violent men are more likely than others to be HIV-infected. See for example, Durevall and Lindskog (2015) and Heise and McGrory (2016).

Thank you for the comment.

It is true that there are studies that question the bidirectional association between IPV and positive HIV serology. Although from our understanding, the two papers mentioned do not completely rule out the possibility of an association, but rather emphasise the importance of considering the woman’s partner’s sexual behaviour. That is, interventions should also focus on changing men’s sexual behaviour.

Nevertheless, it is true that we did not mention studies that counter the association between IPV and HIV infection. This is because our study focus was not HIV infection, but rather ART adherence. We therefore believe it is more relevant for us to discuss studies which support or reject that IPV has an influence on ART adherence. We understand that this might not have been clear before and we hope that including the theoretical framework helps to clarify it.

16) A drawback of the study is that women who have not entered an ART program or have dropped out are not included in the sample. This should be made clear early on, particularly since it is likely to create a bias that weakens the association. It should also be commented on in Limitations. Now it is mentioned in Conclusion, which is odd.

Noted. In our view, ‘not including women who have not entered the ART program in our sample’ is not a limitation because our aim was to determine IPV’s influence on ART adherence. Our target was therefore HIV-positive women who were already on ART. We agree that IPV could be a factor that prevents women from initiating ART (HIV care cascade step 3) and we have referenced, within the introduction section, some studies that highlight this (Pg. 4 from line 64).

With regard to not including women who have dropped out of the ART program, we have moved the mentioned drawback to the limitation section (Pg. 18 line 386). We have also retained it in the conclusion section because we believe it offers a point for future research.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Michelle L Munro-Kramer

3 Mar 2021

PONE-D-20-21450R2

Intimate partner violence is a barrier to antiretroviral therapy adherence among HIV-positive women: Evidence from government facilities in Kenya

PLOS ONE

Dear Dr. Biomndo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Thank you for your edits to this manuscript. As noted by both reviewers, the reviews addressed the majority of the reviewers' comments. There are still a few minor outstanding comments that should be addressed before publication. We look forward to receiving the revision.

Please submit your revised manuscript by Apr 17 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Michelle L. Munro-Kramer, PhD, CNM, FNP-BC

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: (No Response)

Reviewer #4: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Yes

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: The authors have responded well to many of the previous reviewers’ comments. I believe that the manuscript can be forwarded to the editor for final approval, provided some small changes are made. Most significant among these are the expansion of the conceptual model in the Introduction and the explanation of a few key findings in the Discussion.

Introduction:

• The conceptual model is still lacking in my opinion. There are three distinct ways in which IPV may lead to negative uptake of health services, including ART. I refer the authors to the seminal WHO conceptual model contained in the 2013 Global and regional estimates of violence against women: prevalence and health effects of intimate partner violence and non-partner sexual violence report.

Methods:

• Although I personally disagree with the decision not to use multilevel modeling, the authors justify this decision well and there is no reason to suspect this decision meaningfully changed the results or their interpretation.

• I recommend moving the justification for using the stepwise regression approach to the Methods section from the Limitations section

Discussion:

• What are the authors’ hypotheses regarding the mechanisms or reasons behind why women who fought back and experience controlling behavior have reduced ART adherence? This should be discussed.

Reviewer #4: The revised version of the paper is fine and I have only some very minor comments.

On line 106-108 the authors write that “We set a minimum duration of six months since beginning ART to recruit women who were accustomed to the ART routine, in an effort to reduce factors affecting adherence that may be related to the initiation stages of ART.” I would like to have some more arguments. Why would using a much smaller duration affect the results? There would be more noise, but you would have more observations and I assume that the correlation with IPV would not be affected. Did you test using a shorter duration?

I do not understand this part. “We also did not include clinics as a fixed effect because this would lead to empty cells due to limited sample size. However, we included clinic as an independent variable as part of our sensitivity analysis” Fixed effects can be described as a dummy for each unit (clinic), which is what is used in the sensitivity analysis.

The authors have carried out estimations that are not reported, but they never state that they are not reported, such as the analysis of women experiencing IPV in the last 12 months. I think these results, and the sensitivity analysis, should be included in the on-line appendix, which now only contains one table.

The authors write that “However, this finding should be considered cautiously, since the tertiary education subgroup had only 49 respondents, which led to small cell numbers for some predictor combinations.” But 49 observations sound sufficient. And why would the cell for the tertiary education subgroup have fewer than 49 observations in some four reported regressions?

In table 2, the p-value for Partner’s HIV status in model 3 and 4 are very different even though the estimates are very similar: 1.60 0.97 – 2.62 0.64; 1.60 0.98 – 2.63 .062. Typo?

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

Reviewer #4: Yes: Dick Durevall

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Apr 21;16(4):e0249813. doi: 10.1371/journal.pone.0249813.r006

Author response to Decision Letter 2


19 Mar 2021

Reviewer’s comments

Reviewer #3

The authors have responded well to many of the previous reviewers’ comments. I believe that the manuscript can be forwarded to the editor for final approval, provided some small changes are made. Most significant among these are the expansion of the conceptual model in the Introduction and the explanation of a few key findings in the Discussion.

Introduction:

• The conceptual model is still lacking in my opinion. There are three distinct ways in which IPV may lead to negative uptake of health services, including ART. I refer the authors to the seminal WHO conceptual model contained in the 2013 Global and regional estimates of violence against women: prevalence and health effects of intimate partner violence and non-partner sexual violence report.

Thank you for highlighting this. We have decided to add a paragraph on Pg.5 from line 88. In this paragraph we describe the different pathways in which IPV directly and indirectly affects women’s health and how this could link to ART adherence. We have taken into account the abovementioned conceptual model.

Methods:

• Although I personally disagree with the decision not to use multilevel modeling, the authors justify this decision well and there is no reason to suspect this decision meaningfully changed the results or their interpretation.

Noted

• I recommend moving the justification for using the stepwise regression approach to the Methods section from the Limitations section.

Done. Please see Pg. 10 line 206

Discussion:

• What are the authors’ hypotheses regarding the mechanisms or reasons behind why women who fought back and experience controlling behavior have reduced ART adherence? This should be discussed.

Noted. Our results show that adjusting for controlling behaviour, women who fought back during an IPV encounter were more likely to report reduced odds of ART adherence than those who are never violent. Violence by women who are exposed to IPV is not uncommon as studies show it is one of the means through which some women defend themselves and their children [1-3]. Since we know that women who are exposed to IPV adopt different physical and nonphysical ways of protecting themselves, we cannot confidently draw any conclusions about the mentioned sub-group of women without having further assessments.

Our results suggest that the act of fighting back during an IPV encounter has no effect on ART adherence. This is evident by the fact that there is no effect when adjusted for physical and sexual IPV. However, a negative effect is seen when adjusted for controlling behaviour, which speaks more to the environment. We interpret this as being reflective of the underlying and underestimated detrimental effect controlling behaviour has, and encourage further research. One way would be through assessing the home environment in which the controlling behaviour occurs. Moreover, we believe that the negative effect on optimal adherence which is seen when adjusted for emotional IPV and controlling behaviour, furthers our rationale that it is not the IPV act itself, but rather living within an environment where IPV occurs, that affects a woman’s ability or motivation to adhere to ART.

We nevertheless realise our error in not making this clear in the beginning and have added a few lines explaining this in Pg 18 from line 343.

Reviewer #4

The revised version of the paper is fine and I have only some very minor comments.

a) On line 106-108 the authors write that “We set a minimum duration of six months since beginning ART to recruit women who were accustomed to the ART routine, in an effort to reduce factors affecting adherence that may be related to the initiation stages of ART.” I would like to have some more arguments. Why would using a much smaller duration affect the results? There would be more noise, but you would have more observations and I assume that the correlation with IPV would not be affected. Did you test using a shorter duration?

Thank you for this comment. We would like to address this in two ways. Firstly, we did not test using a shorter duration because it would have meant that we needed to also measure factors that are negatively associated with ART initiation. This includes but is not limited to: the woman’s knowledge and understanding of HIV/ART, the woman’s denial, fears or expectations of HIV/ART, challenges to the practical demands of treatment (e.g. scheduling, reluctance to start lifelong treatment), health worker-patient relations, adverse drug reaction, and regimen adjustments. Additionally, women who attend the ART program are referred through Home Based Counselling and Testing (HBCT), Voluntary Counselling and Testing (VCT) or Provider Initiated Testing and Counselling (PITC). This already puts them at different levels in terms of acceptance of HIV diagnosis, CD4 count levels, and their motivation to take up or adhere to treatment. All these together with the IPV related variables would inflate the number of independent variables we assess in our sample of 408 women.

Secondly, from a practitioner’s perspective, because of the aforementioned factors, we expect some instability in ART adherence in the first few months. According to the national guidelines for antiretroviral therapy in Kenya [4], it is after six months following initiation of ART that a patient is expected to have sufficient knowledge of HIV/ART and the importance of adherence, and is therefore expected to be compliant. Before six months, the guidelines recommend frequent appointments (two weeks, monthly) to assess proper administration and storage of the medication, to assess patient’s clinical progress, and to counsel on adherence. It is also during this duration that the patient is closely monitored for adverse drug reactions, drug resistance, and adjustments to the treatment regimen is made. At six months, a CD4 count is recommended as a follow up to the baseline CD4 count which was conducted when the HIV status was confirmed. We therefore expected that the women who participated in our survey had sufficient knowledge of HIV, medication compliance, and the importance and benefits of ART adherence.

The number of observations were not affected since we had no trouble achieving the target sample size using the inclusion criteria. Nonetheless, your comment has made us realise that this is information that may not be clear to the readers and so we have added a brief explanation on Pg. 6 from line 113.

b) I do not understand this part. “We also did not include clinics as a fixed effect because this would lead to empty cells due to limited sample size. However, we included clinic as an independent variable as part of our sensitivity analysis” Fixed effects can be described as a dummy for each unit (clinic), which is what is used in the sensitivity analysis.

Noted. We did not include clinics as a fixed effect in our main analysis because adding twelve additional dummy coded variables to the analysis would have led to predictor combinations with very few to zero observations. In this case, the specified model would have smoothed over the points where only limited data is available, which in turn would have led to a decrease in confidence in the respective models’ estimators. We have added this explanation on Pg 10 line 216.

c)The authors have carried out estimations that are not reported, but they never state that they are not reported, such as the analysis of women experiencing IPV in the last 12 months. I think these results, and the sensitivity analysis, should be included in the on-line appendix, which now only contains one table.

Noted. We have included the tables showing the results of the multiple regression models using only women who experienced IPV in the last 12 months, and the one including clinics is the Supplementary Information.

d) The authors write that “However, this finding should be considered cautiously, since the tertiary education subgroup had only 49 respondents, which led to small cell numbers for some predictor combinations.” But 49 observations sound sufficient. And why would the cell for the tertiary education subgroup have fewer than 49 observations in some four reported regressions?

Thank you for the comment. Out of all the women we randomly surveyed only 49 had tertiary education. When we combined education level with the other predictor variables there were instances where the cells were empty or had very few observations. For example, there were no women with tertiary education who were in a relationship and had experienced physical IPV. Only two women with tertiary education were in a polygamous marriage.

Nonetheless, we decided to rephrase the previous statement to read ‘..However, it should be noted that the tertiary education subgroup had only 49 respondents, which led to small cell or no numbers for some predictor combinations’ (Pg.18. line 339)

e) In table 2, the p-value for Partner’s HIV status in model 3 and 4 are very different even though the estimates are very similar: 1.60 0.97 – 2.62 0.64; 1.60 0.98 – 2.63 .062. Typo?

Thank you for bringing this to our attention. It was indeed a typo and we have corrected it.

References

1. Swan SC, Snow DL. The development of a theory of women's use of violence in intimate relationships. Violence against women. 2006 Nov;12(11):1026-45. PubMed PMID: WOS:000241242700005. English.

2. Downs WR, Rindels B, Atkinson C. Women's use of physical and nonphysical self-defense strategies during incidents of partner violence. Violence against women. 2007 Jan;13(1):28-45. PubMed PMID: WOS:000242973100003. English.

3. Denson TF, O'Dean SM, Blake KR, Beames JR. Aggression in Women: Behavior, Brain and Hormones. Front Behav Neurosci. 2018 May 2;12. PubMed PMID: WOS:000431189600001. English.

4.-NASCOP. Guidelines for Antiretroviral Therapy in Kenya. Nairobi Kenya: National AIDS and STI Control Program, 2011.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 3

Michelle L Munro-Kramer

26 Mar 2021

Intimate partner violence is a barrier to antiretroviral therapy adherence among HIV-positive women: Evidence from government facilities in Kenya

PONE-D-20-21450R3

Dear Dr. Biomndo,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Michelle L. Munro-Kramer, PhD, CNM, FNP-BC

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for your continued work attending to the reviewers' comments. The clarity of the manuscript has been greatly improved over the course of revisions. I am happy to accept this manuscript for submission.

Reviewers' comments:

Acceptance letter

Michelle L Munro-Kramer

30 Mar 2021

PONE-D-20-21450R3

Intimate partner violence is a barrier to antiretroviral therapy adherence among HIV-positive women: Evidence from government facilities in Kenya

Dear Dr. Biomndo:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michelle L. Munro-Kramer

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Propotional stratified sampling based on the number of women on ART and location of clinic.

    (DOCX)

    S2 Table. Multiple regression models of factors associated with ART adherence among women who experienced IPV in the last 12 months.

    (DOCX)

    S3 Table. Multiple regression models of factors associated with ART adherence including clinics as a predictor variable.

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Plos_adherence.pdf

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    We have uploaded our data set to Zenodo and it is available via the following URL: https://zenodo.org/record/4135394#.YGNt469Kg2x (DOI: 10.5281/zenodo.4135394).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES